

























Submitted in partial fulfillment of the requirements for  
the degree of Doctor of Philosophy 
under the Executive Committee of the  








































Network based analysis of genetic disease associations 
Sarah Gilman 
 
Despite extensive efforts and many promising early findings, genome-wide association studies 
have explained only a small fraction of the genetic factors contributing to common human diseases. 
There are many theories about where this “missing heritability” might lie, but increasingly the prevailing 
view is that common variants, the target of GWAS, are not solely responsible for susceptibility to 
common diseases and a substantial portion of human disease risk will be found among rare variants. 
Relatively new, such variants have not been subject to purifying selection, and therefore may be 
particularly pertinent for neuropsychiatric disorders and other diseases with greatly reduced fecundity.  
Recently, several researchers have made great progress towards uncovering the genetics behind 
autism and schizophrenia. By sequencing families, they have found hundreds of de novo variants 
occurring only in affected individuals, both large structural copy number variants and single nucleotide 
variants. Despite studying large cohorts there has been little recurrence among the genes implicated 
suggesting that many hundreds of genes may underlie these complex phenotypes. The question 
becomes how to tie these rare mutations together into a cohesive picture of disease risk. 
Biological networks represent an intuitive answer, as different mutations which converge on the 
same phenotype must share some underlying biological process. Network-based analysis offers three 
major advantages: it allows easy integration of both common and rare variants, it allows us to assign 
significance to collection of genes where individual genes may not be significant due to rarity, and it 
allows easier identification of the biological processes underlying physical consequences. 
This work presents the construction of a novel phenotype network and a method for the 
analysis of disease-associated variants. This method has been applied to de novo mutations and GWAS 
results associated with both autism and schizophrenia and found clusters of genes strongly connected 
by shared function for both diseases. The results help elucidate the real physical consequences of 
putative disease mutations, leading to a better understanding of the pathophysiology of the diseases.  
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Common Diseases and Human Genetic Variation 
At the start of the century, the popular theory held that for common diseases there must exist 
common genetic variants which caused the disease, or at least increase individual susceptibility. Around 
this time, the International HapMap project was formed with the goal of describing patterns of variation 
in the human genome. They examined common single nucleotide polymorphisms (SNPs), and defined 
blocks of genetic code, or haplotypes, which could be used to characterize the genome of an individual 
[1, 2]. With this knowledge and the decreasing cost of SNP genotyping, it became possible to run 
genome-wide association studies (GWAS), in which genotypes from a large cohort of unrelated subjects 
with a particular disease were compared to genotypes from healthy subjects in the hopes of finding the 
common genetic factors associated with the disorder [3-5].  
GWAS have had many notable successes, finding genes associated with age-related macular 
degeneration [6] and a well-documented association between APOE and late-onset Alzheimer’s disease 
[7]. In 2007, the Wellcome Trust Consortium published a Genome-wide association study of 14,000 
cases of seven common diseases and 3,000 shared controls, one of the seminal works in this field, the 
first to sequence thousands of subjects [8]. Along with several meta-analyses, this study implicated 
many susceptibility loci for Type 1 Diabetes and Crohn’s disease [9, 10]. After several years, hundreds of 
loci have been associated with different phenotypes and many interesting disease genes uncovered [11-
14].  
It has become clear however that common variants alone cannot explain genetic risk for all 
common diseases [15]. For many disorders with high heritability, different studies frequently implicate 
different genomic loci. Most confirmed loci may have only a moderate effect on disease risk ratios, 
showing very little impact on disease risk for the individual. Even when taken together, GWAS results 





where this missing heritability may be found, with some suggesting a new focus on environmental 
factors and others calling for more advanced models of epistasis, the interactions between SNPs.  
Recently, however, there has been increasing interest in favor of an alternate theory of disease 
susceptibility: “common disease – rare variant”. This theory posits that a collection of rare variants, 
occurring in genes with similar function or a shared biological pathway, might lead to a common 
phenotype despite their differences. One researcher has even demonstrated in silico that rare 
mutations might cause spurious associations between common SNPs and diseases [18]. Rare mutations 
are less frequent because they occurred more recently and therefore have not had time to affect a 
substantial portion of the population. However, they might have a larger impact on disease risk and 
odds ratios as they have not been exposed to purifying selection yet, and can therefore be more 
deleterious than common variants [16, 19-23]. This might be particularly relevant for neuropsychiatric 
disorders where causal mutations will face particularly strong pressures from natural selection due to 
greatly reduced fecundity [24].  
Unfortunately, rare variants pose new problems for researchers. The foremost issue is how to 
locate them; while the cost of sequencing is dropping, it is impossible to estimate the study size needed 
to detect variants of unknown frequency. Many researchers have addressed this by returning to family 
studies and searching for de novo variants, or novel mutations, in the affected individual by comparison 
with their healthy parents and siblings. A second problem is that even relatively large studies show very 
low recurrence among the genes implicated by de novo variants. This makes it difficult to assign 
significance to the association between disease and mutation [25]. Finally, while it may be possible to 
trace the biological implications of single mutations, such studies are difficult and costly. Some 
association studies report lists of putative disease genes, trusting future studies to confirm the 





Biological networks represent an intuitive answer to many of these problems. The underlying 
idea is that for different mutations to converge on the same phenotype they must share cellular 
processes [26, 27]. This shifts the focus of genetic studies from finding disease mutations to finding 
biological pathways perturbed by disorders [28-31]. This has three key advantages. First, it becomes 
possible to assign significance to a collection of mutations where it might be impossible to assign it to 
individual elements while also making it easier to identify unrelated spurious results. Second, it becomes 
possible to consider multiple types of mutations together, unifying common and rare variants through 
their shared functions. Finally, viewing mutations through the lens of biological process brings the focus 
to predicting real physical consequences, and it is these consequences that will lead to a better 
understanding of human disease.  
The major contribution of this work will be a novel method for analysis of disease associated 
variants which not only helps to select true disease associations from spurious results, but also helps 
define biological functions underlying diseases. The major limitation is that this work will require pre-
existing sets of putative disease associations discovered through unbiased genome-wide assessment; 
several such results have been published, but there remain many diseases that have not been the 







1.1. Thesis Overview  
Pleiotropy: gene contribution to multiple diseases 
In the study of human disease, pleiotropic genes, those which affect susceptibility to multiple 
conditions, are of special importance as they impact disease co-occurrence models and drug side-
effects. The first step in understanding pleiotropy is finding the mechanisms that allow genes to 
contribute to multiple diseases. There are two competing models for how genes exhibit pleiotropy: 
through proteins capable of multiple molecular functions, the elemental biochemical activities of 
proteins, or through the reuse of such functions in multiple biological processes and contexts. This 
chapter examines the evidence for both hypotheses, ultimately favoring the latter; participation in 
multiple high-level processes and pathways represent the key to understanding pleiotropy in human 
disease genes. These results suggest that the use of such processes would assist in the prioritization and 
understanding of disease genes. 
 
A functional network of phenotypic interactions 
With an increasing catalog of genes effecting disease susceptibility, there is a growing need for 
methods to combine and interpret those results in order to better understand their underlying biological 
effects. Functional networks represent the perfect framework for promoting this understanding; shared 
function can be used to reduce noise among putative disease genes, predict real physiological changes, 
and potentially improve our understanding of drug targets and side-effects. Rather than use an existing 
network of function annotations or protein-protein interactions, this chapter proposes the construction 
of phenotypic network, one which combines multiple sources of evidence into likelihoods that gene 
pairs share phenotypic assignments. The network is validated using the task of prioritizing disease 
genes, and we demonstrate the value of combining evidence rather than relying on a single existing 






Network based analysis of de novo copy number variants associated with autism  
Preliminary results from a large study of high-functioning autistic children reveal a collection of 
de novo copy number variants (CNV) associated with the disease, but understanding theser variants 
remains challenging. Using the developed phenotypic network, this chapter proposes a method for 
network-based analysis of genetic associations (NETBAG) to address some of the issues of studying rare 
and de novo disease mutations. The method finds a significant cluster of genes primarily related to 
synapse development, axon targeting, and neuron motility, highlighting perturbed synaptogenesis as the 
heart of autism. In addition, the results support the hypothesis that significantly stronger functional 
perturbations are required to trigger the autistic phenotype in females compared to males. This work 
provides an important proof of the principle that the biological underpinnings of complex human 
phenotypes can be identified by a network-based functional analysis of rare genetic variants. 
 
Diverse genetic variations converge on functional gene networks involved in schizophrenia 
Different types of genetic variation have shown a significant contribution to schizophrenia 
susceptibility, confounding the search for a cohesive explanation of disease etiology. Using the 
developed phenotype network and analysis method (NETBAG), we combine the results of GWAS studies, 
de novo copy number variants (CNV) and single nucleotide variants (SNVs) to find a cluster of 
functionally related genes highly expressed in the brain. This cluster – related to axon guidance, 
neuronal cell mobility, synaptic function, and chromosomal remodeling – implicates many of the same 
biological processes underlying autism. A comparative analysis of CNVs associated the two diseases 
suggests that while the molecular networks implicated in these distinct disorders may be related, the 






Function and phenotype across de novo genetic mutations associated with autism  
The analysis of de novo single nucleotide variants (SNVs), implicates many hundreds of genes for 
autism spectrum disorders (ASD). These are converging on core biological pathways underpinning the 
disease, such as synaptic plasticity, dendritic growth, and neuronal signaling. The next step is to use this 
knowledge to better understand the wide phenotypic variation that ASD represents. We explore this 
problem using the information available in the Simons Simplex Collection (SSC), a collection of de novo 
mutations in affected individuals alongside a substantial array of measurements relevant to disease 
severity. This chapter highlights the biological functions associated with the disease but more 
importantly the consequences of mutation on individual phenotype. We find a wide range of biological 
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2. Pleiotropy: gene contribution to multiple diseases 
2.1. Introduction  
In the study of human disease, pleiotropic genes, those which affect susceptibility to multiple 
conditions, are of special importance; they are crucial to understanding disease co-occurrence models 
and predicting side effects for drugs with specific gene targets [1, 2]. In addition, it has been proposed 
that such genes play a central role in human senescence as genes which are advantageous in early life 
may exhibit deleterious effects later [3, 4]. Pleiotropy is common with almost 30% of genes in the 
disease database Online Mendelian Inheritance in Man (OMIM) implicated in more than one phenotype, 
and more than one third of these were implicated in more than two phenotypes. 
The first step in understanding pleiotropy is finding the mechanisms that allow genes to 
contribute to multiple diseases. Two potential models were developed in the context of yeast genes and 
growth phenotypes: genes may produce products which participate in multiple molecular functions that 
contribute to different conditions, or genes may produce products with a single function that is reused 
in multiple biological processes and phenotypes [2, 5, 6]. In these models, molecular functions represent 
the elemental biochemical activities of proteins while biological processes represent cellular-level 
activities. Both can range from very broad categories which apply to thousands of genes, to more 
specific annotations that apply to only a handful of genes.  
In this chapter, we perform three experiments to explore which mechanism represents the 
more likely path to pleiotropy in human disease genes. First, we examine disease specific alleles to see if 
separate diseases are significantly tied to unique protein domains as this would support multiple 
molecular functions as the key to pleiotropy. Second, we calculate Spearman rank correlations between 
the number of disease associations for a gene and the number of Gene Ontology (GO) annotations in 
either the molecular functions or biological process category. This correlation should indicate which 





as a proxy for human disease we look for the same correlations over a larger set of genes from a recent 
study of yeast phenotypes [7].  
The major goal of this chapter will be to define the likely mechanism for pleiotropy among 
human disease genes. While both models undoubtedly play some role, we find more evidence for the 
latter, that is that pleiotropic genes are more likely to have a single molecular function that is reused in 
multiple biological processes and phenotypes, rather than produce gene products acting in multiple low-








2.2.1. Disease mutations and protein domains 
We hypothesize that if genes contribute to multiple diseases through multiple molecular 
functions, disease causing mutations are more likely to be appear in separate functional protein 
domains. For example, the protein PSAP is associated with Methachromatic leukodystrophy and Atypical 
Gaucher disease, each of which has multiple single nucleotide polymorphisms (SNPs) associated with 
increased risk of the disease. The SNPs for these diseases are localized in separate domains within the 
PSAP protein (Figure 2.1).  
 
 
In order to test this idea, we downloaded known disease polymorphisms (SNPs) from UniProt 
and protein domains from InterPro and examined the strength of the associations between diseases and 
domains. We used only those genes with at least two domains and two diseases, leaving a total of 355 
genes containing 1418 domains and 6338 SNPs and associated to 1051 diseases. We used Fisher’s exact 
test to determine for each disease and domain if the number of disease SNPs in the domain was 
significant compared to the number of disease SNPs outside the domain based on the size of the domain 
and the protein. Under our null hypothesis the disease and domain are not related, with SNPs as likely 
to appear outside the domain as inside. Thus a low p-value indicates that the SNPs are more likely to 
 
Figure 2.1: Sample SNPs in protein domains. Protein sequence for SAP_HUMAN with domains 
from InterPro shown in purple and disease associated SNPs shown in red and blue. Three SNPs 
associated with Metachromatic leukodystrophy fell into one protein domain, while the two 






appear in the domain, and suggests that the disease is associated with the molecular function of that 
domain.  
We found that only 10.8% of the diseases were associated to a domain, at a p-value of less than 
0.05. In addition, only 6.8% were uniquely associated to a domain; that is there were no other diseases 
associated with this domain at such a low p-value. Less than 0.5% of genes had multiple diseases 
mapped to separate domains.  
To assess the significance of this finding, we randomly reassigned SNP positions within each 
gene, allowing us to randomize the locations of disease mutations while maintaining the number of such 
mutations across genes and diseases. In 1000 trials we found that the mean number of diseases 
associated with a domain was 4.6% (±0.5) and the mean number associated uniquely to a domain was 
4.3% (±0.5). This gives our results with the actual disease labels an estimated p-value less than 0.005. 
However, the number of genes with all diseases uniquely tied to separate domains remained similar to 
our results using actual disease associations, 0.2% (±0.2).  
We noted that 40% of these genes are related to forms of cancer which may exhibit unique 
behavior from other diseases, so we split these into a separate subset and repeated our analysis. 
Cancers showed weaker associations between diseases and domains, with 2.8% percent of diseases 
associated to domains, and 1.4% associated uniquely to domains. By contrast, the data without cancers 
showed strong associations between diseases and domains, with 16.5% percent of diseases associated 
to domains and 9.5% associated uniquely to domains. This suggests that cancerous genes may be less 
likely than other disease genes to exhibit pleiotropy through multiple molecular functions.  
While this result demonstrated a significant association between functional domains and 
disease it is not a strong one as very few diseases were uniquely associated to a functional domain. 
Furthermore, not all genes are complex enough to have multiple functional domains. The data from 





10% of these diseases were significantly tied to the protein’s one functional domain with a p-value of 
0.05 or less. Therefore having multiple functional domains is far from the only source of pleiotropy in 
disease genes. 
 
2.2.2. Gene Ontology functional annotations and Pleiotropy 
For our next analysis, we used diseases annotations in OMIM which contains 2212 genes 
associated with 2495 phenotypes. While these are not specific locations, we can examine the correlation 
between the number of diseases associated with each gene and certain key annotations to indicate the 
source of pleiotropy. First, we focus on pleiotropy though multiple molecular functions. For this we 
examine the correlation between the number of diseases in OMIM and the number of annotations from 
the Gene Ontology (GO) classified under ‘molecular function’ as well as the number of enzyme codes 
associated with the gene in the Kyoto Encyclopedia of Genes and Genomes (KEGG) and the number of 
protein domains associated with the gene in InterPro. We found no correlation between disease count 
and the number of enzyme codes (Spearman’s rank correlation coefficient: r = 0.026, two-tailed 
significance: p = 0.53; Figure 2.2) although this was not unexpected as only about 10% of genes had 
multiple enzyme codes. We do find modest but significant correlations with both molecular function 
(Spearman’s r = 0.121, p = 3e-8; Figure 2.2) and the number of domains (Spearman’s r = 0.096, p = 1e-4; 
Figure 2.2). This supports our finding of disease-specific domains from the UniProt alleles by showing 
genes with multiple functional domains have more associated diseases. 
We contrast this analysis by considering the correlation between the number of diseases in 
OMIM and the number of annotations from GO classified under ‘biological processes’ and ‘cellular 
component’ as well as the number of tissues expressing the gene in the TiGER database and the number 
of distinct interaction partners in the Human Protein Reference Database (HPRD). These measures 





contexts. We found strong correlations with biological processes (Spearman’s r = 0.228, p = 0; Figure 
2.2) as well as the number of interaction partners (Spearman’s r = 0.170, p = 3e-11; Figure 2.2), but only a 
modest correlation with the number of cellular components (Spearman’s r = 0.088, p = 5e-5; Figure 2.2) 
and the number of tissues (Spearman’s r = 0.098, p = 0.006; Figure 2.2).  
 
  
Figure 2.2: Associations between disease gene pleiotropy and various descriptors. Plotted is the 
average number of annotations in each descriptor binned by the number of diseases associated 
with each gene. Bins represent genes associated 1 disease (1556 genes), 2 diseases (370 genes), 
3 diseases (143 genes) and 4 or more diseases (143 genes). Error bars show one standard error 
from the mean. (A) Descriptors which would imply pleiotropy was linked to multiple molecular 
functions: number of protein domains in the gene, number of molecular functions in the Gene 
Ontology (GO), and the number of enzyme codes in KEGG. (B) Descriptors which would imply 
pleiotropy was linked to molecular function being reused in multiple biological processes: 
number of protein-protein interaction partners for the gene, number of biological processes or 
cellular components in GO, and the number of human tissues expressing the protein (TiGER). 
There is some correlation between the number of diseases associated with a gene and the 
number of domains or molecular functions, but stronger correlations are seen with the number 
of biological processes and interaction partners.  
 
Confounding this analysis, we note a high correlation between the number of molecular 
functions and the number of biological processes or interaction partners (Spearman’s r = 0.471, p = 0; r = 





that the correlations between disease count and the number of molecular functions or protein domains 
were insignificant when controlled by the number of biological process and greatly reduced when 
controlled by the number of interaction partners (Partial correlation coefficient c = 0.016, p = 0.49; c = 
0.077, p = 0.003 respectively). By contrast, the correlation between disease count and the number of 
biological process remained strong when controlled by the number of molecular functions or protein 
domains (c = 0.195, p = 1e-19; c = 0.200, p = 1e-15 respectively). We also found that correlations between 
disease count and the number of biological processes or interaction partners were largely independent 
with strong partial correlations in both directions (Process controlled by partner count: c = 0.179, p = 2e-
12; Partners controlled by process count: c = 0.117, p = 5e-6).  
As in our first experiment, we divided our genes into cancers and other diseases. In the OMIM 
database, more than 90% of genes were associated with other diseases and given their dominance we 
were not surprised to find that this set of disease genes had correlations comparable to our original 
results. Cancer genes however showed some interesting differences. We found a much higher 
correlation between multiple disease associations and the number of protein domains (Spearman’s r = 
0.265, p = 0.002), although given our earlier results showing that cancers were less likely to be 
significantly associated with particular domains, this may indicate that cancer causing genes are more 
likely to have multiple functional domains not that these domains are tied to separate diseases. We also 
found that among cancer genes there was no significant correlation between disease count and the 
number of molecular functions, but strong correlation with the number of biological process 
(Spearman’s r = 0.280, p = 3e-4), cellular components (Spearman’s r = 0.217, p = 0.007), and the number 
of interaction partners (Spearman’s r = 0.332, p = 6e-5).  
Because the correlations with biological process are more robust, we conclude that participation 





the gene to participate in multiple higher level processes and interaction pathways. Thus functional 
reuse in multiple environments is likely to be more important to disease gene pleiotropy.  
 
2.2.3. Pleiotropy in yeast genes  
In the OMIM database, genes with high pleiotropy are rare; there are only 72 genes associated 
with more than four diseases. In order to expand our analysis to a data set with higher levels of 
pleiotropy, we used slow-growth phenotypes from yeast in the place of human diseases. A recent study 
attempted to uncover phenotypes for nonessential yeast genes by measuring growth rates of mutants in 
the presence of small molecules. This data set contained 4327 genes covering 161 conditions, with over 
87% of genes relating to at least two conditions and nearly 50% relating to more than 4 conditions [7]. 
We used similar annotations for yeast genes as with human disease genes. For molecular function this 
included: GO annotations under the heading ‘molecular function’, enzyme codes (EC) and protein 
domains associated with each gene through Munich Information Center for Protein Sequences (MIPS). 
For biological process this included: GO annotations under the heading ‘biological process’ and ‘cellular 
component’, and of the number protein-protein interaction partners manually curated from results of 
yeast two-hybrid experiments [7].  
Similar to OMIM genes, we found strong correlations between the number of slow growth 
conditions and the number of biological processes (Spearman’s r = 0.244, p = 0), cellular components 
(Spearman’s r = 0.132, p = 0), interaction partners (Spearman’s r = 0.245, p = 1x1e-11), and a small but 
significant correlation with molecular function (Spearman’s r = 0.101, p = 3e-11). By contrast, we did not 
see a correlation between the number of slow growth conditions and the number of protein domains 
(Spearman’s r = 0.010, p = 7e-1), although this correlation was weak among human disease genes as well. 
Similar to our previous results, the correlation between the number of slow growth conditions and the 





biological processes (c = 0.022, p = 0.55; c = 0.040, p = 8e-3 respectively), while the correlations between 
the number of slow growth conditions and the number of biological process or interaction partners are 




There are some important limitations to our approach. First, we were not able to guarantee that 
all associated GO terms were non-redundant. We did address this problem to some degree by using the 
GO hierarchy to remove parent terms, however, not all redundancy can be accounted for this way as 
sibling terms are often similar. We considered restricting our annotations to various levels in the GO 
hierarchy, so that very specific siblings might be replaced by a single more general parent term, but this 
would not guarantee that all redundancy was removed and in fact may remove many non-redundant 
sibling annotations. Trials using different levels of the GO hierarchy as a cutoff had little or no effect on 
the correlations observed.  
Another weakness of our method is that we considered diseases independent despite the fact 
that many may be related. For example, we would consider gene AGRP, associated with leanness and 
obesity, to have the same pleiotropy as gene COX15, associated with Cardiomyopathy and Leigh 
syndrome, a neuro-metabolic disorder. While both genes are associated with two distinct diseases, it 
seems obvious that the former pair of diseases have more in common with each other than the latter 
pair. Unfortunately OMIM does not have a disease classification scheme which we could utilize to 
account for this problem.  
Despite these limitations we feel our results strongly suggest that participation in multiple high-
level processes and pathways represents the key to understanding pleiotropic disease genes, 





with separate functional domains, however, this was far from conclusive as many pleiotropic proteins 
had only one functional domain. In addition, the fact that correlations between multiple diseases and 
multiple biological processes were stronger and more independent than the correlations between 
multiple diseases and multiple molecular functions indicates that this is the more common source of 
pleiotropy. These patterns were confirmed in yeast genes, in contrast with earlier studies [6] which may 
have been limited due to a smaller set of phenotypes.  
This conclusion has important implications for the study of human disease genes. First, it 
suggests that finding disease specific alleles may be problematic as a mutation which disrupts a single 
molecular function may affect multiple diseases [5, 6]. This will be particularly problematic for genes 
with simpler products consisting of few functional domains. Second, our results suggest that using 
shared processes or high level pathways would be a good way to prioritize disease genes. Such methods 
are being applied to the problem of finding disease genes from the very noisy results of genome-wide 
association studies [8-11]. Third, our results confirm the importance of varied protein-protein 
interaction partners as a source of pleiotropy in disease genes, and support the idea that targeting 
context-specific interactions rather genes will lead to more effective drug therapies with fewer side 
effects [5, 6]. Finally, understanding the shared biological processes or interaction pathways can help 
our understanding of how diseases relate to each other and increase our understanding of a patient’s 







Disease mutations and protein domains 
For our analysis of disease distinct domains, we used the disease SNPs available through UniProt 
mapped to protein domains from Interpro. Any overlapping domain annotations were assigned to a 
single domain.  We used Fisher’s exact test with the length of the gene, length of the domain and the 
number of disease SNPs inside and outside the domain to measure the association between domain and 
disease. To assess the significance of our results, we ran 1000 trials where we reassigned the disease 
labels within each gene and measured the association between disease and domain again. 
o Uniprot: release 57.6 - http://www.uniprot.org/docs/humsavar 
o InterPro: release 22.0 - ftp://ftp.ebi.ac.uk/pub/databases/interpro/  
 
Gene Ontology functional annotations and Pleiotropy 
Disease genes were downloaded from the National Center for Biotechnology Information (NCBI) 
through OMIM which contained 2212 genes in 2495 diseases or phenotypes, with 656 genes 
participating in more than one disease. GO annotations were also downloaded from NCBI. We removed 
the root “unknown” annotations and any redundant ancestor annotations using the “is_a” and 
“part_of” relationships to determine ancestry. We also downloaded enzyme codes from the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) database, protein domains from the InterPro database, 
tissue indicators from the TiGER database, and protein-protein interactions available through the 
Human Protein Reference Database. 
All correlations were measured using the Spearman rank algorithm built into R. Partial 
correlation coefficients were calculated with an R extension available from Georgia Institute of 
Technology (http://www.yilab.gatech.edu/pcor.html). 
o GO annotations: ftp://ftp.ncbi.nlm.nih.gov/gene/ (01/2009) 





o TiGER: http://bioinfo.wilmer.jhu.edu/tiger/ (09/2009) 
o HPRD: http://www.hprd.org/download (01/2009) 
 
Pleiotropy in yeast genes   
Yeast genes were obtained from a study which analyzed 1144 chemical genomic assays for 
heterozygous and homozygous deletions. The purpose of this study was measure the growth rate of 
mutants in the presence of small molecules to gain “insight into gene dispensability, multidrug 
resistance, and gene functions.” [7] Our final data set included 4327 genes which displayed slowed 
growth with a p-value of 1e-5 or less. These genes covered 161 conditions, and we found 3780 genes 
present in multiple conditions. See Hillenmeyer et al. for details on the small molecules tested. 
 For yeast annotation data we used the same sources as an earlier study by He and Zhang. GO 
annotations came from a list mined from literature, enzyme codes from the Yeast Enzyme Commission 
(EC), and predicted functional domains from Munich Information Center for Protein Sequences (MIPS). 
Protein-protein interactions were downloaded from Han et al. based on yeast two-hybrid experiments, 
protein complexes, and in silico interaction predictions known interactions in the MIPS database. [12] 
o GO: http://www.ncbi.nlm.nih.gov/pubmed/17942445  
o Domains: (06/2009)  ftp://ftpmips.gsf.de/yeast/catalogues/eccat/eccat_data_20062005 
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3. A functional network of phenotypic interactions 
3.1. Introduction  
With an increasing catalog of genes effecting disease susceptibility, there is a growing need for 
methods to combine and interpret those results in order to better understand their underlying biological 
effects. Functional networks represent the perfect framework for promoting this understanding. The 
core concept behind this type of analysis is that if two genes contribute to a single phenotype they must 
share some biological process, one directly relevant to the disease etiology [1, 2]. Shared function can 
be used to reduce noise among putative disease genes, predict real physiological changes, and 
potentially help fulfill the promise of personalized medicine, improving our understanding of drug 
targets and side-effects [3-8]. 
In recent years, the focus has been on using network methods to interpret the results of 
genome-wide association studies (GWAS) [3, 4]. In GWAS, large populations of sick and healthy 
individuals are compared in order to find haplotypes, or genetic regions, which increase susceptibility to 
a particular disease. One of the major issues is that by implicating haplotypes rather than specific 
mutations, GWAS results often leave the causative gene in question. Various methods prioritize likely 
candidate genes from an implicated genomic region using functional similarity to previously confirmed 
disease genes (Endeavour [9], [10, 11]), similarity with genes from other implicated regions (GRAIL [12]), 
or the existence of protein interactions with genes from other implicated regions (DAPPLE [13]). 
Network methods have also been applied to other tasks; for example, many methods use 
protein-protein interactions (PPI) networks to better predict disease associations and draw conclusions 
about the topological features of disease genes in the network itself [14]. Other methods search for 
protein interactions specifically targeted by cancer [15-17]. There have been methods which predict 





of the disorder [18, 19]. Finally, some methods ignore the question of finding new associations and focus 
instead on explaining the biological impact of previously documented disease genes [20-22].  
Here, we propose that instead of using an existing network of protein interactions or functional 
annotations, we will combine multiple sources into a network where every gene pair is assigned a score 
based on the likelihood that these genes contribute to a shared phenotype. We use a method similar to 
that used in the construction of functional PPI networks for several model organisms [23-25], although 
we differ from these methods by predicting shared phenotype rather than direct interaction. This 
chapter will focus on construction and validation of the network, while later chapters will demonstrate 
its utility in the prioritization of genomic regions and in the analysis of rare variants associated with 
disease. The major goals of this chapter will be: 
 
(1) Demonstrate that functional descriptors, such as shared functional annotations or protein 
interaction partners, can be used to predict the likelihood that two genes contribute to a shared 
phenotype by performing a leave-one-out validation on a collection of known disease gene sets.  
 
(2) Verify that the naïve combination of likelihood scores from various evidence sources performs 
better than any single functional descriptor, and demonstrate a simple de-weighting heuristic to 
control for the fact that edges within a collection of genes that share a single disease are not 







3.2. Results and Discussion 
We build a network in which each pair of genes is connected by score proportional to the 
likelihood ratio that these genes either share a phenotype or not. This network was built using individual 
sources of evidence, for example the existence of a PPI between the genes, or using a naïve sum over 
multiple sources of evidence. In order to verify that these scores capture true phenotypic connections, 
we apply the network to the task of prioritizing known disease genes from their genomic regions. We 
used a collection of diseases from the OMIM database, excluding any phenotypes used in training our 
network; this left 596 genes over 205 phenotypes. We performed leave-one-out cross validation where 
each gene was placed among its 99 closest chromosomal neighbors and all 100 genes were prioritized 
based on network connections to the remaining genes from that disease.  
Figure 3.1 shows the number of tests where the true disease gene appeared at, or below, a 
certain rank using single-source networks (described in Methods) and our combined phenotype 
network. The combined network consistently out-performs all individual sources. The poor performance 
of phylogenetic profiling and chromosome co-clustering was due to limited coverage; in most tests none 
of the 100 genes had any network connections to the disease genes making the ranking essentially 
random. The same problem effected sequence alignment, shared protein domains, and tissue 
expression where only a handful of tests had some network connections between disease genes. 
Removing these sources did not significantly impact the performance of the combined network, so they 
were kept as they do provide some value in extremely rare cases. The best performing sources were 








Figure 3.1: Disease gene predictions by evidence source. For each trial, a disease gene was placed 
among its 99 closest neighbors and the entire genomic region was prioritized based on the sum of all 
connections from the candidate to the remaining genes from that disease. Area under curve (AUC) was 
calculated based on the number of trials at or below each rank. Performance using a naïve sum over all 
functional descriptors is shown in black. Other lines represent performance using only single sources of 
functional descriptor. These included: Direct protein-protein interaction between candidate and disease 
genes (PPI Interaction); overlap between protein-protein interaction partners (PPI Partners); shared 
annotations in the Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), tissue 
expression database (TiGER), or protein domains (InterPro); Blast sequence similarity; phylogenetic 







It should be apparent that edges in the phenotype network are not wholly independent; that is, 
if a candidate gene has strong connections to one disease gene, it is likely to have strong connections to 
other genes associated with the same disease. To account for this dependence, we employed a simple 
de-weighting heuristic previously described in Lee et al. [23]. Figure 3.2 and Table 3.1 show the percent 
of trials at or below each rank under each scoring scheme. While performance of naïve scoring is slightly 
higher at the first rank, the two are virtually equivalent after that demonstrating that our de-weighting 






Trials at or below rank 
Rank Deweighted Naïve 
1 40.3 42.1 
2 49.0 49.5 
3 54.9 54.9 
4 57.0 57.4 
5 59.6 59.9 
6 61.7 61.4 
7 63.1 63.3 
8 64.6 64.9 
9 66.1 66.1 
10 66.8 66.9 
50 87.8 87.9 
AUC 85.3 85.3 
 
 
Figure 3.2: Naïve versus Deweighted scoring. Results from the cross validation trials where each disease gene 
was placed among its 99 closest neighbors and the entire genomic region was prioritized based on 
connections in the combined phenotype network from the candidate to the remaining genes from that 
disease. Results using naïve scoring (red) where final score is the sum of all edges to the disease genes, and 
using dewieghted scoring (black) where final score is weighted to reflect dependence between disease genes.  
Table 3.1: Selected ranks from figure 3.2.  
 
 
Finally, we note that having been identified in OMIM our trial genes may have been the subject 





stronger connections in our underlying phenotype network than the average gene. As they are being 
compared to random genes, this might artificially inflate our results. To test this, we select decoy genes 
for prioritization in three ways: we take neighboring genes as described to simulate a genomic region, 
we take 99 randomly selected genes, and finally we take 99 random genes from other diseases in 
OMIM. For the latter two cases, we used 100 random sets to estimate rank of each trial gene. Figure 3.3 
plots the percent of trials at or below each rank based on decoy genes selected, and Table 3.2 shows 
area under curve for based on the network source, scoring method, and decoys genes selected. We note 
that there is virtually no difference between neighboring genes and randomly selected genes showing 
that genes are not subject to any bias merely by being neighbors of a well-studied disease gene. 
However, performance declines when decoys are other disease genes, particularly using our combined 
phenotype network. While our combined network still has value over individual networks this results 
demonstrates that it is important to consider a gene’s overall connectivity in the phenotype network.  
 
Figure 3.3: Disease gene predictions using different decoy genes. Results from the cross validation trials 
where each disease gene was placed among its 99 decoys and all candidate genes were prioritized based 
on connections in the combined phenotype network to the remaining genes from that disease. Results 
were obtained using deweighted scoring. Results using neighboring genes as decoys (black), randomly 




















































































Combined phenotype network 0.853 0.859 0.782 0.853 0.857 0.779 
PPI Interaction 0.755 0.755 0.639 0.753 0.755 0.640 
Shared KEGG annotations 0.710 0.709 0.697 0.709 0.709 0.695 
Shared GO annotations 0.701 0.720 0.682 0.727 0.719 0.682 
Shared PPI partners 0.611 0.613 0.676 0.615 0.612 0.675 
Shared TiGER tissue annotations 0.573 0.567 0.597 0.577 0.556 0.591 
Blast sequence similarity 0.556 0.575 0.573 0.572 0.573 0.573 
Shared InterPro annotations 0.529 0.531 0.604 0.528 0.532 0.604 
Phylogenetic profile similarity 0.507 0.499 0.498 0.511 0.501 0.509 




These results demonstrate three important points. First, our method of defining a likelihood 
ratio does accurately reflect phenotypic associations between disease genes. Second, while there are 
some individual networks which capture phenotypic connections well, the naïve combination of all data 
outperforms individual sources. Finally, when scoring connections between groups of genes, a simple 








3.3. Methods  
Network Construction 
 In our underlying phenotype network every gene pair is connected by a score proportional to 
our expectation that the two genes share a phenotype. This score is based on evidence sources such as 
shared functional annotations or protein-protein interaction partners. The final score is calculated 
according the following formula: 
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Where for each evidence source, s, there is a score, Esij, which is used to predict the probability that this 
pair shares a disease phenotype, P(D|E), or not, P(~D|E). Although the prior odds ratio, P(D)/P(~D) is not 
precisely known, it is constant and since our results rely on comparing edges in the network, they are 
not sensitive to the exact value of this ratio. 
 For each source of evidence, we trained a model to estimate the ratio (P(D|E) / P(~D|E)). For 
this task, we collected gene pairs with a shared phenotype from a carefully curated set of disease genes 
[2]. This set contained 476 genes associated with 132 genetic diseases, for a total of 1183 unique pairs. 
For gene pairs without a shared phenotype we used 500,000 randomly selected gene pairs. We selected 
this large number of pairs both to reflect our belief that sharing a phenotype was unlikely and also to 
dilute the effect of any false negatives selected due to imperfect knowledge about human disease. Gene 
pairs were binned by their evidence scores and we counted pairs with and without a shared phenotype 
in each bin. We fit these values with a combination of linear and quadratic formulas which were then 
used to estimate the ratio for novel gene pairs. For any gene pair without a score in the evidence source, 
for example two genes with no associated GO terms, we used a default score equivalent to the median 





 When considering network connections from a candidate gene to a collection of n disease 
genes, we used a simple de-weighting heuristic to account for the fact that these edges are not 
independent. Under this scheme, the edges from one gene to the collection are sorted by their strength 
and de-weighted according to their position in the sorted array. That is:  
                   ∑
                        
 
 
   
   
A similar method was previously used in the construction of functional protein-protein interaction 
networks for several model organisms [23-25].  
 
Network Sources 
Shared Annotations: We considered shared annotation from a number of publicly available 
databases. Specifically, we used the descriptions of protein function and cellular localization in Gene 
Ontology (GO), enzyme codes and pathways defined in Kyoto Encyclopedia of Genes and Genomes 
(KEGG), protein domains from the InterPro database, tissue expression from TiGER database. For these 
sources, we used a score based on the number and strength of shared annotations.  
First, we calculated a weight for every annotation based on its specificity, defined as the number 
of genes annotated with a particular term (Mt ) divided by the number of genes with annotations (N). 
Second, we summed the weights for all terms shared by a given gene pair using Fisher’s omnibus 
procedure (see the equation below) to obtain a final score, Eij
annotation. This method has been used 
previously to prioritize candidate genes based on their similarity to known disease genes [9]. In the case 
of GO terms, we utilize the GO annotation hierarchy, so that if a gene was assigned a specific term we 
also assigned it to all more general parents of that term; this ensures that general terms have more gene 
assignments than their more specific children terms, giving them a lower weight. 
   
            ∑      (
  
 ⁄ ) 
                                      






Protein-protein interactions: We used the following databases in our analysis of protein-protein 
interactions (PPI): BIND, BioGRID, DIP, HPRD, InNetDB, IntAct, BiGG, MINT, and MIPS. We derived two 
different measures based on PPI networks. First, we checked if a given gene pair directly interacts, and 
counted the number of PPI databases that contain that interaction. This measure, Eij
PPI was a good 
predictor of a shared phenotype, but naturally covered a very small fraction of gene pairs. Second, for 
each pair of genes, gi and gj, we compared the number of interactions they share with other human 
proteins. Specifically, for each gene I we found a vector I=(i1, i2, …,in) where ia is the number of databases 
which contained a PPI between genes I and A. We then used the Tanimoto coefficient, an extension of 
cosine similarity, to measure this distance between vectors I and J, Eij
neighbors, where     is the scalar 
product of two vectors and ‖ ‖ is the vector magnitude.  
   
           
    
‖ ‖  ‖ ‖         
   
 
Sequence homology: To detect sequence homology between each gene pair, we used BLAST.  
The homology-related score for a gene pair was the sequence homology for the most significant (lowest 
E-value) BLAST alignment. 
Phylogenetic profiles and chromosomal co-clustering across genome locations:  We used two 
genomic context correlations which are commonly used to infer functional similarity between genes: 
phylogenetic profiles and chromosomal co-clustering calculated previously by Chen et al. [26]. For 
phylogenetic profiles, this work used binary vectors, describing the presence or absence of gene 
homologs in 70 diverse species. The gene profiles were compared using Pearson’s correlation to 
produce a score. For chromosomal co-clustering, the mean distance (in base pairs) between gene 






Information was downloaded from the following resources: 
 Gene Ontology annotations from NCBI (01/2009 – ftp://ftp.ncbi.nlm.nih.gov/gene/) 
 Pathways and enzyme codes from Kyoto Encyclopedia of Genes and Genomes (KEGG) database 
(01/2009 – ftp://ftp.genome.jp/pub/kegg/genes/organisms/hsa/) 
 Domains from InterPro database (01/2009 – ftp://ftp.ebi.ac.uk/pub/databases/interpro/) 
 Tissue indicators from the TiGER database (09/2009 – http://bioinfo.wilmer.jhu.edu/tiger/) 
 Protein-protein Interactions: 
o BIND with protein complexes (08/2009 – http://bond.unleashedinformatics.com/) 
o BioGRID interactions (08/2009 – http://www.thebiogrid.org/downloads.php)  
o DIP interactions (10/2009 – http://dip.doe-mbi.ucla.edu/dip/) 
o HPRD interactions (10/2009 – http://www.hprd.org/) 
o InNetDB interactions (05/2009 – http://hanlab.genetics.ac.cn/sys/intnetdb) 
o IntAct (10/2009 – http://www.ebi.ac.uk/intact/) 
o BiGG metabolic interactions (04/2009 – http://gcrg.ucsd.edu/Downloads ) 
o MINT (05/2009 – http://mint.bio.uniroma2.it/mint/) 









1. Schadt, E.E., Molecular networks as sensors and drivers of common human diseases. Nature, 
2009. 461(7261): p. 218-23. 
2. Feldman, I., A. Rzhetsky, and D. Vitkup, Network properties of genes harboring inherited disease 
mutations. Proc Natl Acad Sci U S A, 2008. 105(11): p. 4323-8. 
3. Cantor, R.M., K. Lange, and J.S. Sinsheimer, Prioritizing GWAS results: A review of statistical 
methods and recommendations for their application. Am J Hum Genet, 2010. 86(1): p. 6-22. 
4. Hardy, J. and A. Singleton, Genomewide association studies and human disease. N Engl J Med, 
2009. 360(17): p. 1759-68. 
5. Sorger, P.K. and B. Schoeberl, An expanding role for cell biologists in drug discovery and 
pharmacology. Mol Biol Cell, 2012. 23(21): p. 4162-4. 
6. Barabasi, A.L., N. Gulbahce, and J. Loscalzo, Network medicine: a network-based approach to 
human disease. Nat Rev Genet, 2011. 12(1): p. 56-68. 
7. Cho, D.Y., Y.A. Kim, and T.M. Przytycka, Chapter 5: Network biology approach to complex 
diseases. PLoS Comput Biol, 2012. 8(12): p. e1002820. 
8. Loscalzo, J. and A.L. Barabasi, Systems biology and the future of medicine. Wiley Interdiscip Rev 
Syst Biol Med, 2011. 3(6): p. 619-27. 
9. Aerts, S., et al., Gene prioritization through genomic data fusion. Nat Biotechnol, 2006. 24(5): p. 
537-44. 
10. Franke, L., et al., Reconstruction of a functional human gene network, with an application for 
prioritizing positional candidate genes. Am J Hum Genet, 2006. 78(6): p. 1011-25. 
11. Freudenberg, J. and P. Propping, A similarity-based method for genome-wide prediction of 
disease-relevant human genes. Bioinformatics, 2002. 18 Suppl 2: p. S110-5. 
12. Raychaudhuri, S., et al., Identifying relationships among genomic disease regions: predicting 
genes at pathogenic SNP associations and rare deletions. PLoS Genet, 2009. 5(6): p. e1000534. 
13. Rossin, E.J., et al., Proteins encoded in genomic regions associated with immune-mediated 
disease physically interact and suggest underlying biology. PLoS Genet, 2011. 7(1): p. e1001273. 
14. Navlakha, S. and C. Kingsford, The power of protein interaction networks for associating genes 
with diseases. Bioinformatics, 2010. 26(8): p. 1057-63. 
15. Vandin, F., E. Upfal, and B.J. Raphael, Algorithms for detecting significantly mutated pathways in 
cancer. J Comput Biol, 2011. 18(3): p. 507-22. 
16. Chuang, H.Y., et al., Network-based classification of breast cancer metastasis. Mol Syst Biol, 
2007. 3: p. 140. 
17. Mani, K.M., et al., A systems biology approach to prediction of oncogenes and molecular 
perturbation targets in B-cell lymphomas. Mol Syst Biol, 2008. 4: p. 169. 
18. Lage, K., et al., A human phenome-interactome network of protein complexes implicated in 
genetic disorders. Nat Biotechnol, 2007. 25(3): p. 309-16. 






20. Holmans, P., et al., Gene ontology analysis of GWA study data sets provides insights into the 
biology of bipolar disorder. Am J Hum Genet, 2009. 85(1): p. 13-24. 
21. Torkamani, A. and N.J. Schork, Pathway and network analysis with high-density allelic 
association data. Methods Mol Biol, 2009. 563: p. 289-301. 
22. Subramanian, A., et al., Gene set enrichment analysis: a knowledge-based approach for 
interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A, 2005. 102(43): p. 15545-
50. 
23. Lee, I., et al., A probabilistic functional network of yeast genes. Science, 2004. 306(5701): p. 
1555-8. 
24. Lee, I., et al., A single gene network accurately predicts phenotypic effects of gene perturbation 
in Caenorhabditis elegans. Nat Genet, 2008. 40(2): p. 181-8. 
25. Jansen, R., et al., A Bayesian networks approach for predicting protein-protein interactions from 
genomic data. Science, 2003. 302(5644): p. 449-53. 
26. Chen, L. and D. Vitkup, Predicting genes for orphan metabolic activities using phylogenetic 








4. Network based analysis of de novo copy number variants associated with autism  
4.1. Introduction 
Autism represents one of the most common neurological disorders in our society today [1]; the 
combined prevalence of autistic spectrum disorders (ASD) has been steadily increasing for several 
decades, due in part to better detection strategies, and now approaches 1%. Despite an estimated 
heritability as high as 90% [2], genome-wide association studies have implicated only a handful of genes 
[3, 4], and agreement between published findings remains poor [5]. Even taken as a collection these 
variants explain only a small fraction of overall disease risk. It is likely that a substantial portion of the 
“missing heritability” can be accounted for by rare structural variations such as copy number variants 
(CNV) [6]. Among such events, de novo variants offer special promise, as they are more likely than 
inherited events to contain a causative mutation, and a gene relevant to disease etiology [7-11]. 
The main challenge in the analysis of de novo CNVs is precisely their rarity; the vast majority of 
the observed genetic events are unique and consequently not statistically significant by themselves. In 
addition, each CNV event may cover multiple genes most of which have no relevance to the disease. 
Finally, while it may be possible to trace the biological implications of a single mutation, this task is more 
difficult with a large number of variants. 
We addressed these problems with a network based approach, NETBAG (NETwork Based 
Association of Genetic variants). In brief, we used the defined network of phenotypic connections in 
which all gene pairs are connected with a score proportional to the likelihood ratio that they either 
contribute a shared phenotype or not (Figure 4.1a). All putative disease variants are mapped to the 
corresponding genes in the phenotype network (Figure 4.1b) where true causative genes from a single 
disease should form a strongly interconnected cluster. A greedy search algorithm is employed to find 
high scoring clusters among implicated genes (Figure 4.1c) with limitations on the number of genes 





many genes, from dominating the cluster. To evaluate the significance of the disease cluster found, 
random genomic events are generated and the same greedy algorithm is used to find clusters using 
these events (Figure 4.1d); P-values are assigned to disease clusters based on a distribution of scores 
from the randomized clusters which are then corrected for multiple hypothesis testing due to 
considering clusters of different sizes.  
This method achieves three important goals:  
 
(1) By limiting the number of genes each CNV may contribute to the cluster, we select the one or 
two genes most relevant to the disease. Furthermore, since we consider clusters of various 
sizes, the final selection may ignore less relevant events altogether. Importantly, the method 
makes these selections without any previous knowledge of autism genetics.  
 
(2) By considering the cluster as a whole, we are able to assign significance even if all events are 
unique and thus not significant by themselves. In addition, gene contribution to the cluster 
score is not uniform but instead proportional phenotypic connections which tie a gene to the 
cluster, which allows us to evaluate the importance of individual genes to the disease etiology. 
 
(3) As the genes in our network are linked through shared function, the underlying biological 
pathways relevant to the disease will be more distinct than if we were considering a collection 








Figure 4.1: The NETBAG method. (A) A background network is constructed in which nodes represent 
human genes and edges represent the likelihood that two genes participate in a shared phenotype. (B) 
One or two genes are selected from each of de novo CNV region (green) to form a cluster. The genes are 
mapped to the likelihood network and a combined score is calculated for each cluster based on 
interactions between genes forming the cluster. (C) A greedy search procedure is used to identify the 
cluster with maximal score. (D) The significance of the cluster with maximum score is determined by 
comparing it to the distribution of maximal scores from randomly selected genomic regions (blue) with 








4.2.1. Autism associated networks  
The approach outlined in Figure 4.1 was applied to the experimental CNV dataset described in a 
recent analysis of de novo CNVs associated with ASD [12]. From these events, we identified statistically 
significant clusters allowing each event to contribute either one or two genes (Figure 4.2, P-value = 0.03 
for one gene per event, P-value = 0.02 for two genes per event). If genes forming the high scoring 
clusters were removed from the input, no other significant clusters were detected among remaining 
genes. In addition, Levy et al. also identified de novo events in the unaffected siblings of autistic 
individuals, and rare inherited events in autistic children and their parents. No statistically significant 
clusters were obtained using either of these sets (rare inherited P-value = 0.6, sibling P-value = 0.3).  
Analysis of the established annotation resources – Swiss-Prot [13], GeneCards 
(www.genecards.org), WikiGenes (www.wikigenes.org), IHOP [14] – suggests that a significant fraction 
of genes in the identified clusters are known to be active in the brain or have been previously implicated 
in neurodegenerative and psychiatric disorders. Between 50-70% of genes in the identified clusters have 
been previously associated to the brain in this fashion (Figure 4.2, orange genes), compared to only 
~20% of the all genes within the de novo CNV regions (P-value < 10-3, see Table 4.3 for functional 
description of cluster genes). 
The contribution of each gene to the cluster score is not uniform. While some genes have strong 
interactions with many genes in the cluster, others have relatively weaker functional connections. Each 
gene’s contribution to the final score can be captured as a de-weighted sum of the edges from that gene 
to all other genes in the cluster, such that the final contribution for a gene is the strongest edge from 
that gene plus half of the second strongest edge plus one third of the third strongest edge and so on. 
The size of each gene in Figure 4.2 is proportional to that score. In addition, we performed Markov Chain 





gene a score proportional to its membership in strongly interconnected clusters (see Methods). This 





Figure 4.2: NETBAG gene clusters found in de novo CNV regions associated with autistic individuals. In the figure, 
genes (nodes) with known functions in the brain and nervous systems are colored in orange (see Table 4.3 for 
functional information about all genes shown). Node sizes represent the importance of each gene to the overall 
cluster score. Importance was determined by taking the weighted sum of all edges from that gene to each other 
cluster gene. Edge widths are proportional to the prior likelihood that the two corresponding genes contribute to a 
shared genetic phenotype. For clarity, we show only the two strongest edges from each node. (A) The highest 
scoring cluster obtained using the search procedure with up to one gene per each CNV region. (B) The cluster 
obtained using the search with up to two genes per region. 
 
 
4.2.2. Gender Bias in autism variants 
 One of the striking characteristics of autism is the male-to-female incidence ratio, potentially as 
high as 7:1 for high-functioning ASD [15]. It has been previously suggested that stronger genetic 
perturbations are required, on average, to trigger an autistic phenotype in females than males, due to 





rare de novo CNVs from female subjects are significantly more important for the overall cluster score, 
compared to genes implicated by male subjects (see Figure 4.3, One-tail Mann-Whitney test, female > 
male, P-value=0.013). Thus genes disrupted in female subjects were more central to the disease cluster 
or more related to its core functions, supporting the hypothesis that females require more functionally 





Figure 4.3: Functional importance of genes perturbed by CNV events in females and males. Autism is a 
disease with strikingly different prevalence in males versus females, especially for high functioning children. In 
Simons Simplex Collection (SSC), analyzed by Levy et al., the ratio of males to females is 7:1. It was proposed 
that, due to a currently unknown mechanism(s), females may be more resistant to autism-causing genetic 
perturbations. Our results are consistent with this hypothesis as the genes from CNV events observed in 
females made more significant contribution to the cluster score, i.e. they interact more strongly with other 
genes in the cluster. A) The identified cluster is shown with children gender indicated by node shapes.. Round 
nodes represent genes coming from the CNV events observed exclusively in males, square nodes from 
females, and diamond nodes come from genomic regions perturbed in both males and females. B) 
Distributions of gene contributions for genes perturbed in males and females CNV (One-tail Mann-Whitney 









4.2.3. ASD network and related sets 
 To confirm that our cluster is associated with existing knowledge about autism, we examined 
manually curated gene sets implicated in autism and intellectual disability [8]. For this analysis, we 
examined the connections in our phenotype network between the cluster and a set of known disease 
genes. These were compared to the connections between random clusters and the same disease sets. 
We found that the cluster using one gene from autism CNVs (Figure 4.2a) is strongly related to genes 
implicated in autism in previous studies (P-value=0.001) and genes associated with intellectual disability 
(P-value=0.017), despite a relatively small overlap between the gene sets (~3%). The cluster was also 
connected (P-value=0.013) to proteins identified experimentally by recent proteomic profiling of 
postsynaptic density (PSD), a neuronal location long thought to be key to autism development [16]. 
  
4.2.4. General Network functions 
 To characterize the specific biological processes related to our cluster in more detail, we 
investigated the strength of functional interactions between the cluster genes and various Gene 
Ontology (GO) categories [17]. We submitted the genes in Figure 4.2b to DAVID (Table 4.1) revealing a 
strong connection with cytoskeleton development and actin formation. In addition, we employed the 
same method described above to assess the connections in our phenotype network between our cluster 
and GO terms, correcting for multiple hypothesis testing using a False Discovery Rate (FDR) procedure. 
The 25 GO categories with highest significance (Table 4.1) also contain many terms related to actin 
network dynamics and reorganization. The remaining terms implicated a diverse collection of molecular 
and cellular processes essential for proper synaptic formation and axon guidance including 







Table 4.1: Gene Ontology terms associated with autism cluster through DAVID 
Gene Ontology Term GO Category P-value 
GO:0007010: cytoskeleton organization Biological process 0.006 
GO:0030054: cell junction Cellular component 0.008 
GO:0030036: actin cytoskeleton organization Biological process 0.011 
GO:0008022: protein C-terminus binding Molecular function 0.014 
GO:0030029: actin filament-based process Biological process 0.018 
GO:0008092: cytoskeletal protein binding Molecular function 0.033 
Gene Ontology terms associated with autism cluster using the phenotype network 
Gene Ontology Term GO Category q-value 
GO:0007015:  actin filament organization Biological process < 0.01 
GO:0030424:  axon Cellular component < 0.01 
GO:0048469:  cell maturation Biological process < 0.01 
GO:0007611:  learning and or memory Biological process < 0.01 
GO:0044456:  synapse part Cellular component < 0.01 
GO:0045202:  synapse Cellular component < 0.01 
GO:0007163:  establishment and or maintenance of cell polarity Biological process 0.025 
GO:0045216:  intercellular junction assembly and maintenance Biological process 0.025 
GO:0019201:  nucleotide kinase activity Molecular function 0.025 
GO:0005912:  adherens junction Cellular component 0.025 
GO:0007409:  axonogenesis Biological process 0.025 
GO:0016323:  basolateral plasma membrane Cellular component 0.025 
GO:0030041:  actin filament polymerization Biological process 0.025 
GO:0051258:  protein polymerization Biological process 0.025 
GO:0021700:  developmental maturation Biological process 0.025 
GO:0030863:  cortical cytoskeleton Cellular component 0.027 
GO:0000904:  cellular morphogenesis during differentiation Biological process 0.027 
GO:0005925:  focal adhesion Cellular component 0.027 
GO:0030427:  site of polarized growth Cellular component 0.027 
GO:0032271:  regulation of protein polymerization Biological process 0.027 
GO:0031175:  neurite development Biological process 0.027 
GO:0048666:  neuron development Biological process 0.027 
GO:0030055:  cell matrix junction Cellular component 0.027 
GO:0030832:  regulation of actin filament length Biological process 0.027 
GO:0030036:  actin cytoskeleton organization and biogenesis Biological process 0.027 
Table 4.1: Gene Ontology (GO) terms highly connected to the clusters in Figure 4.2. Terms were found 
by submitting cluster genes to DAVID, or by an analysis of the connections in our phenotype network 
between the cluster and genes annotated with a particular term. Multiple hypothesis correction, due 
to examination of hundreds of GO terms, was done in the former case through Bonferroni correction, 






4.2.5. Synaptic contacts and Dendritic Morphology 
At the core of the processes described above is the development and maturation of synaptic 
contacts in the brain. Thus the relationships between cluster proteins can be better appreciated when 
considered in the context of molecular interactions involved in formation and maturation of the 
excitatory (glutamatergic) synapse (Figure 4.4). Excitatory synaptic connections are formed between 
axons and dendritic spines, which are complex and dynamic post-synaptic structures containing 
thousands of proteins [18, 19]. The formation, maturation, and elimination of dendritic spines—and 
their precursors, filopodia—lie at the core of synaptic transmission and memory formation [20, 21]. 
Although Figure 4.4 shows a dense and interconnected web of molecular interaction, the processes 
depicted can be understood in terms of several signaling and structural pathways, many of which 
converge on the regulation of the growth and branching of the actin filament network essential for spine 
structuring and morphogenesis. 
 The initial contacts between axons and dendrites are mediated by specific adhesion-related 
proteins, such as neurexin (e.g. NRXN1, genes perturbed by de novo CNVs in ASD are italicized here and 
below) and neuroligin (e.g. NLGN3) [22]. On the postsynaptic side of an excitatory synapse, these initial 
axon-dendrite contacts ultimately develop into a complex and dense structure, the postsynaptic density 
(PSD), dominated by several types of glutamate receptors (such as AMPA and NMDA), various 
scaffolding proteins (DLG4/PSD95, DLG2, SHANK2/3, SynGAP1, DLGAP2) and trafficking/signaling 
proteins (CNND2). In total, PSD contains many hundreds of distinct proteins [16, 23]. From these 
contacts, information for activity-dependent regulation of spine morphology is passed through an 
intermediate level of signaling protein, such as Rho family [24] of small GTPases: RhoA/B, Cdc42, Rac1, 
to downstream targets ultimately connected (for example, through LIMK1 and PAK1/2/3) to proteins 





is regulated postsynaptically by many guanine exchange factors (GEFs, such as GDI1) and GTP activating 
proteins (GAPs).  
 Another signaling pathway, the WNT pathway, plays a crucial role in diverse processes 
associated with formation of neural circuits [26], and is known to be directly involved in the regulation 
of dendrite morphogenesis [27, 28]. WNT signaling is accomplished through the canonical branch (DVL, 
AXIN1, beta-catenin) and the non-canonical branch (DVL1/2/3, Rac1, and JNK); both of these pathway 
branches converge on regulation of actin network morphogenesis. Similar to WNT, the reelin signaling 
also plays a prominent role in the context of autism phenotype and specifically dendritic spine 
morphogenesis [29, 30]. Signaling by secreted extracellular RELN protein acts though VLDR and Apoer2 
receptors and the PI3K/Akt pathway [31] regulating the mammalian target of rapamycin (mTOR) 
pathway [32, 33]. Another important pathway converging on mTOR is MAPK3/ERK, which is activated, in 
part, by Ras and NF1. mTOR integrates various inputs from upstream growth-related pathways, and is 








Figure 4.4: Important genes associated with the morphogenesis of dendritic spines. Dendritic spines are 
dynamically forming protrusions from a neuron’s dendrite which mediate excitatory connection to axons and 
determine synaptic strength. Proteins shown in the figure play crucial roles in formation of physical contacts 
between axons and dendrites, organization of postsynaptic density (PSD), and signaling processes controlling spine 
morphology. Many of the signaling pathways ultimately converge on the regulation of the growth and branching of 
the actin filament network, which is essential for spine structural remodeling. The proteins encoded by genes from 
the identified functional cluster (Figure 4.2) are shown in yellow, other genes hit by de novo CNV from Levy et al., 
in blue, and genes previously implicated or discussed in the context of autism are circled in orange 
 
 
4.2.6. Consequences for Dendritic Morphology 
 Considering our cluster genes from the perspective of the functional molecular network (Figure 
4.4) allowed us to investigate likely morphological consequences of some CNVs events. There is growing 
evidence that changes in dendritic spine morphology play an important role in a number of neurological 





linked to schizophrenia [36-38]. On the other hand, an increase in spine size or density has been 
connected to Fragile X syndrome, a disorder related to autism [39, 40]. Following the logic that CNV 
deletions should decrease the dosage of the perturbed genes and duplications should increase it, we can 
infer—based on the structure and regulatory logic of the functional network in Figure 4.4—the 
morphological effects of 13 gene perturbations on dendritic spines. Specifically, we found that in 11 out 
of 13 cases (~85%) the gene perturbations caused by the observed CNV events should increase either 
dendritic spine growth or their density (Table 4.2). This result is consistent with recent findings that 
autistic individuals have increased spine density in portions of their cerebral cortex [41, 42] and possibly 
a local brain over-connectivity [43]. 
  
Table 4.2: Likely impact on dendritic growth for ASD genes 
Gene  Literature Support  CNV Event Likely impact 
AXIN1 
A negative regulator promoting the phosphorylation and destruction of β-
catenin [44], which is necessary for dendritic growth [45] deletion Increase 
BAIAP2 
Knockdown of BAIAP2 through RNA reduces the density, length and width of 
dendritic spines [46] deletion Decrease 
CRKL Reduction of CRKL block dendrogensis [47] duplication Increase 
CTNNA3 
Alpha-catenein regulates actin-filament assembly , potentially through 
competition with Arp2/3 [48]  duplication increase 
CTNND2 Delta-catenin knockdowns have been shown to increase spine density [49] Deletion increase 
DKK1 
DKK1 can stimulate neurite outgrowth through Frizzled and JNK signaling 
[50] duplication increase 
DVL2 DVL2 knockdown suppresses neurite outgrowth [50] duplication increase 
FLNA 
Actin-binding protein that crosslinks filaments, which is necessary for the 
development of neuronal filopodia [51] duplication increase 
LIMK1 
LIMK1 deficits result in decreased number of dendritic spines or abnormally 
small, thing spines [36, 52] duplication increase 
MAPT 
Overexpression of Tau leads to descreased levels of β-catenin  [53], which is 
necessary for dendritic growth [45] deletion increase 
NDE1 Promotes neuron outgrowth by regulating microtubules [54] duplication increase 
PAK2 
Pak2 phosphorylates LIMK1, inactivating cofilin [55], alternatively Pak2 can 




Stabilizes cytoskeleton and binds it to plasma membrane. Located 
throughout brain where intensity corresponds to the density of neuronal 
cells [56] duplication Increase 
Table 4.2: We examined genes from our cluster to understand whether it is possible to predict a likely 
morphological impact. We found that, based on analysis of our network or previously published results, it is 
possible to infer effects for 13 genes which appeared in our cluster. Two genes (MAPK and CYFIP1) were not 
considered because they appeared in both duplication and deletion events, making their impact uncertain. 
Interestingly, we observed that events affecting 11 out of 13 analyzed genes the observed CNV events should 
increase growth or density of dendritic spines. One further event, a deletion containing gene PAK2, may also 








 Although we discussed cluster proteins in the context of dendritic spine development, many of 
the genes in Figure 4.4 proteins also participate in diverse cellular processes and are reused in the 
context of axon guidance and neuron motility [57]. Such a recycling of proteins is natural because actin 
network dynamics are essential for such processes as growth of axonal filopodia used in searching for 
growth cone guidance cues [58]. The presence of DCC protein in the identified network (Figure 4.2 and 
Figure 4.4), also suggests an important role of perturbed axonal guidance in autism. Although DCC is 
involved in dendrite development [59], this receptor and its signaling protein netrin are essential for 
guiding axons to their final destinations [58]. In addition, several signaling pathways, for example the 
WNT and reelin pathways, also play a prominent role in neuron motility [26, 60] and several specific 
proteins, such as PAKs and LIMK, which regulate the dynamics of actin network, are reused in axonal 
morphogenesis. Consequently, malfunction of many proteins shown in Figure 4.4 may influence autistic 
phenotypes through their role in either dendrite or axon signaling, or possibly a combination of these 
processes. 
 The presented analysis strongly supports the hypothesis that autism is primarily a disease of 
synaptic and neuronal connectivity malfunction [61] with genetic events affecting the whole arch of 
molecular processes essential for proper synapse formation and function. Genes identified by our 
network analysis reveal a striking genetic complexity of autism, similar to that already apparent in many 
cancers [62, 63]. We and others believe this complexity will be a hallmark of many common human 
phenotypes and maladies [64]. In spite of the observed complexity, our study provides an important 
proof of the principle that underlying functional networks responsible for common phenotypes can be 






 The functional network presented in Figure 4.4 contains approximately 70 genes, with about 
40% of them perturbed by rare de novo CNVs observed by Levy et al. As more genetic data are analyzed 
it is likely that the network will growth in size and significance. Considering, for example, that up to a 
thousand [23] distinct proteins are associated with postsynaptic density or that hundreds of different 
GAPs/GEFs modify activity of Rho GTPases associated with actin network remodeling, it is likely that 
many hundreds of genes could ultimately contribute to the autistic phenotype. This estimate is 
consistent with independent estimates based on recurrent mutations and the overall incidence of 
autism in the human population [11, 12]. Deleterious variants in different genes contributing to autistic 
phenotype will almost certainly have different penetrance and vulnerabilities. To illuminate both the 
complete set of genes responsible for ASD and their respective contributions to the phenotype will 









Copy number variants  
The recent analysis by Levy et al. identified 75 rare de novo CNV events. These were mapped to 
746 unique human genes using NCBI build 36. We combined any overlapping events into a single region 
and removed events that did not intersect any genes; we also removed six very large CNV events (length 
>5 Mb). As a result, the final set used for our analysis contained 47 genomic regions intersecting 433 
genes. In addition, Levy et al. also identified de novo CNV events identified from unaffected siblings as 
well as rare CNVs inherited by autistic subjects but not their siblings. The average number of genes 
within each de novo CNV region was ~9, with the median of 3 genes per regions. 
Levy et al. also identified 19 de novo CNV events in siblings of autistic children and 157 rare 
inherited CNV events, those seen a parent and the autistic child but not the seen in the unaffected 
siblings. Appling the preprocessing steps described above resulted in the sibling dataset containing 14 
regions hitting 69 genes, and inherited data containing 156 regions hitting 418 genes. 
 
Greedy Search Algorithm 
Once putative disease genes are mapped to the underlying phenotype network, a greedy 
growth algorithm was used to find strongly connected clusters among these genes (Figure 4.5). 
Specifically, the search algorithm was started from every possible gene in CNV regions, and then at each 
iteration the gene which most increased the cluster score was added. The method allowed only one or 
two genes per each CNV region in the growing cluster; once a region had contributed the limited 
number other genes from that event were ignored. This procedure was run until no further genes could 
be added. At each cluster size, results obtained by starting from different genes were compared and the 





The score for a cluster was the sum of the contributions from each gene it contained. Each 
gene’s contribution was the de-weighted sum of all edges from that gene to other cluster genes. The 
sum included the strongest edge, plus half of the second strongest edge, plus one third of the third 
strongest edge and so on. This heuristic was used to reflect our belief that genes in a cluster will contain 
common functions and therefore their edges are not wholly independent.  
 
Network Significance 
In order to determine the significance of the disease-associated network it was compared with 
results from random genomic events. The randomization procedure preserved either the size in base 
pairs, or the number of genes in each observed in each genomic event. Preserving gene count produced 
more conservative P-values and so this was used throughout our analysis. Once random events were 
generated, the same search algorithm was applied to produce a distribution of cluster scores from 
random genomic events at every possible cluster size.  
Using 10,000 random trials, we first determined the P-value for the highest scoring cluster at 
each size based on the scores of random clusters of the same size. We refer to this as the local P-value. 
The final cluster is the one with the lowest local P-value. Next, we find the lowest local P-value in each 
random trial and used this distribution to assign significance to our local P-value which we refer to this 
as the global P-value. This corrects for multiple hypothesis due to different cluster sizes.  The global P-












Figure 4.5: Illustration of the cluster building procedure used in the NETBAG approach. Gene clusters were built 
using a greedy iterative search, i.e. by adding the gene which most increased the overall cluster score at each 
iteration. (A) A cluster of size 3 is on the left, and genes mapped to five CNV regions are shown on the right. Genes 
in grey cannot be used because either they or other genes from their CNV regions are already in the cluster. Genes 
in blue are still available for the cluster building algorithm. One available gene, X1, has weak connections to the 
cluster. (B) Another available gene from another CNV, Y1, has relatively stronger connections to the cluster when 
compared to X1. (C) Gene Y1 is added to the cluster. (D) The greedy algorithm was started with all possible genes 
within CNV regions (Gene 1, Gene 2 … Gene G) and clusters were grown to a maximum size. NETBAG selects the 
highest scoring clyster at each size (S
Max
i), assigns local P-values (Pi) and selects the cluster with the lowest P-value 
as the final result. 
 
 
Gene contribution to cluster and MCMC simulations 
Contributions of different genes to the score of the identified network vary substantially. 
Because of de-weighting these measurements are largely based on the strength of the two strongest 
edges from that gene. The size of nodes in Figure 4.2 is relative to this score. In addition, we devised a 
formal method to assign weights to individual genes reflecting their contribution to high scoring 
clusters. The method is based on two distributions over networks: pu(C) in which all clusters are equally 
likely, and p(C) in which clusters are assigned a probability relative to the their scores such that high 





likely to appear in clusters sampled from the uniform distribution, pu(C), while genes with stronger 
functional connections to other genomic events are more likely to appear in clusters sampled from the 
non-uniform distribution, p(C). We used Markov-Chain Monte Carlo (MCMC) to sample five million 
clusters from each of the two distributions. Each gene is assigned a score equal to the number of times it 
was seen in non-uniform clusters versus the number of times it was seen in uniform clusters. This 
method accounts not only for an individual gene’s connections but also the number of genes in each 
genomic event. Results were comparable to considering a simple weighted sum of the edges containing 
each gene, although the simulations had the advantage of allowing us to assign weights to genes not 
seen in the selected cluster.  
 
Gene Set Relationship Analysis 
To characterize the identified cluster we investigated its interactions with a collection of defined 
functional sets of human genes, the 5518 gene sets from the MSigDB database which included Gene 
Ontology (GO) categories along with molecular pathways [65]. Using the phenotype network, for each 
gene set we calculated its average interaction to the identified clusters shown in Figure 4.2. To 
determine the significance of the calculated interaction scores we built gene set-specific background 
distributions by generating clusters from the randomized genomic regions with the same gene count as 
in Levy et al. We used the background distribution to assign an empirical P-value for every gene set and 
then applied FDR procedure to address the multiple hypothesis involved in testing all gene sets within 





Table 4.3: Function notes on NETBAG cluster genes 
GeneID Name 2A 2B Neural Documented Protein Function 
26574 AATF Yes Yes No 
Plays a role in apoptosis via interaction with MAP3K12; unclassified 
interactions with aberrant amyloid peptide associated with Alzheimer 
disease 
255926 ADAM5P Yes Yes No Pseudogene; unknown function 
158 ADSL No Yes Yes 
Involved in AMP biosynthesis; point mutations implicated, though 
rare, in autistic individuals [66] 
5205 ATP8B1 Yes Yes No 
Involved in the transport of phosphatidylserine and 
phosphatidylethanolamine across the bilayer; mutations may result 
in epithelial disorders 
8312 AXIN1 No Yes Yes 
Part of the WNT signaling pathway; facilitates phosphorylation of 
beta-catenin with APC and GSK3B. 
10458 BAIAP2 Yes Yes Yes 
Plays a role in CDC42-mediated reorganization of the actin 
cytoskeleton, and may affect neuronal growth-cone guidance 
9031 BAZ1B No Yes No 
Plays a central role in DNA repair acting as marker to distinguish 
repair from apoptosis, and in targeting the WINAC complex to 
acetylated histones; may be involved in Williams-Bueren syndrome 
[67] 
774 CACNA1B Yes Yes Yes 
Voltage-dependent Ca(2+) calcium channel, involved in 
neurotransmitter release; may play a role in directed migration of 
immature neurons; implicated in schizophrenia [68] 
8318 CDC45 No Yes No 
Member of the highly conserved multiprotein complex, including 
Cdc6/Cdc18, important during early steps of DNA replication in 
eukaryotes 
1139 CHRNA7 Yes Yes Yes 
Member of the nicotinic acetylcholine receptors (nAChRs) super-
family, ion channels that mediate fast signal transmission at 
synapses; located in a chromosomal region previously implicated in 
schizophrenia 
81570 CLPB Yes Yes No 
May function as a regulatory ATPase and be related to 
secretion/protein trafficking process 
1394 CRHR1 No Yes Yes 
C-protein coupled receptor that binds neuropeptides, major 
regulators of the hypothalamic-pituitary-adrenal pathway; may have 
protective effect against adult depression [69] 
1399 CRKL Yes Yes Yes 
Shown to activate the RAS and JUN kinase signaling pathways; binds 
to DAB1 to help mediate transduction of Reelin signaling important 
for neuronal positioning [70] 
64478 CSMD1 Yes Yes Yes 
Potential tumor suppressor; highest expression is in brain, may play a 
crucial role in nerve growth cone function [71] 
29119 CTNNA3 Yes Yes Yes 
Alpha-catenin; functions in cell-cell adhesion and regulation of actin-
filament organization, possibly through competition with Arp2/3-
mediated actin polymerization 
1501 CTNND2 Yes Yes Yes 
Delta-catenin; primarily expressed in brain; may be involved in 
neuronal cell adhesion; involved in regulation of neurite outgrowth 
23191 CYFIP1 Yes Yes Yes 
Involved in formation of membrane ruffles and lamellipodia 
protrusions and in axon outgrowth through binding to F-actin 
1630 DCC Yes Yes Yes 
Transmembrane receptor of neutrin-1 ligand; mediates axon 
guidance 
168400 DDX53 Yes Yes Yes 
Primarily expressed in testis, and potentially related to 
tumorigenesis; recently identified as part of x-linked locus associated 
with autism [8] 
22943 DKK1 No Yes Yes 
Involved in embryonic development through its inhibition of the WNT 
signaling pathway; in adults implicated in bone disease, cancer and 
Alzheimer's disease 
1739 DLG1 No Yes Yes 
Post-synaptic scaffolding protein which may be involved in the 





GeneID Name 2A 2B Neural Documented Protein Function 
1740 DLG2 Yes Yes Yes 
Member of the post-synaptic density (PSD) in excitatory synapses; 
plays a role in NMDA receptor signaling and stability of certain 
synapses 
1742 DLG4 Yes Yes Yes 
Key post-synaptic scaffolding protein utilized for clustering/assembly 
of receptors, ion channels, and associated signaling proteins; changes 
in this gene expression were shown to alter the ratio of excitatory to 
inhibitory synapses in hippocampal neurons 
1856 DVL2 No Yes Yes 
Part of the WNT signaling pathway, involved in neural connectivity 
[72] 
79813 EHMT1 No Yes No 
Methylates histone H3, which tags it for transcriptional repression; 
may play a role in the G0/G1 cell cycle transition through silencing of 
MYC- and E2F-responsive genes 
2175 FANCA Yes Yes No 
May operate in a postreplication repair or a cell cycle checkpoint 
function; may be involved in interstrand DNA cross-link repair and in 
the maintenance of normal chromosome stability 
2316 FLNA Yes Yes Yes 
Interacts with actin filaments to remodel the cytoskeleton, effecting 
cell shape and migration; may assist in certain neuroblast migration; 
defects can cause neurological developmental disorders 
56776 FMN2 No Yes No 
Plays a role in cytoskeletal organization and/or establishment of cell 
polarity 
2803 GOLGA4 Yes Yes No 
Encodes a protein localized to the Golgi apparatus, and postulated to 
play a role in Rab6-regulated membrane tethering events, and 
vesicular transport from the trans-Golgi 
64388 GREM2 Yes Yes No 
Encodes a member of the BMP antagonist family, involved in 
organogenesis, body patterning, and tissue differentiation; other 
members of this protein family, although not this gene, implicated in 
axon cone guidance 
2869 GRK5 Yes Yes Yes 
GRK family member whose primary function is to phosphorylate and 
thus deactivate G protein-coupled receptors; mouse knockouts 
displayed an age-dependent neurodegeneration, comparable to early 
Alzheimer disease [73] 
8517 IKBKG No Yes No 
Encodes the regulatory subunit of the inhibitor of kappaB kinase (IKK) 
complex, which indirectly activates genes involved in inflammation, 
immunity, cell survival, and other pathways 
3708 ITPR1 Yes Yes Yes 
Encodes an intracellular receptor for inositol 1,4,5-trisphosphate, 
which mediates calcium release from the smooth endoplasmic 
reticulum; mutations associated with a various cerebellum disorders 
51621 KLF13 No Yes No 
Part of a transcription factor family that binds to C-rich sequences; 
related to inflammation response through activation of RANTES 
expression in T-cells 
3984 LIMK1 Yes Yes Yes 
Phosphorylates and inactivates cofilin, thereby stabilizing the actin 
cytoskeleton; likely to be involved in brain development; implicated 
in the impaired visuospatial constructive cognition of Williams 
syndrome 
7851 MALL No Yes No 
Predominantly localizes in glycolipid- and cholesterol-enriched 
membrane (GEM) rafts, involved in raft-mediated trafficking in 
endothelial cells 
5595 MAPK3/ERK1 Yes Yes Yes 
Member of kinase family which responds to extracellular signals; 
transduces signals from growth factors and key in regulating 
differentiation and proliferation; MAPK kinase pathways associated 
with various diseases including neurodegeneration 
4137 MAPT Yes Yes Yes 
Promotes microtubule assembly and stability, and might be involved 
in the establishment and maintenance of neuronal polarity; 
expressed at various stages and locations in the nervous system; 






GeneID Name 2A 2B Neural Documented Protein Function 
9442 MED27 Yes Yes No 
Component of the Mediator complex, a coactivator involved in the 
regulated transcription of nearly all RNA polymerase II-dependent 
genes; serves as a scaffold for the assembly of necessary elements 
and general transcription factors 
22877 MLXIP Yes Yes No 
Binds DNA as a heterodimer with MLX, and plays a role in 
transcriptional activation of glycolytic target genes; involved in 
glucose-responsive gene regulation; abundant in skeletal muscle 
4629 MYH11 Yes Yes Yes 
A smooth muscle myosin, predominantly found in myocytes; 
functions as a major contractile protein, converting chemical energy 
into mechanical energy through the hydrolysis of ATP; was identified 
as a component of post synaptic density 
54820 NDE1 No Yes Yes 
Plays an essential role in microtubule organization, mitosis and 
neuronal migration; essential for the development of the cerebral 
cortex; may regulate the production of neurons by controlling the 
orientation of the mitotic spindle 
54413 NLGN3 Yes Yes Yes 
Member of a family of neuronal cell surface proteins, binding to beta-
neurexins; involved in the formation and remodeling of central 
nervous system synapses; mutations in this gene may be associated 
with autism and Asperger syndrome  
4867 NPHP1 Yes Yes No 
Interacts with Crk-associated substrate, and appears to function in 
the control of cell division, and in cell-cell and cell-matrix adhesion 
signaling through a complex localized in actin- and microtubule-based 
structures 
9378 NRXN1 Yes Yes Yes 
Functions in the vertebrate nervous system as cell adhesion 
molecules and receptors; plays an important role in formation or 
maintenance of synaptic junctions through binding to neuroligins 
4905 NSF Yes Yes Yes 
Catalyzes the fusion of transport vesicles within the Golgi cisternae; 
neuronal function depends on vesicles fusing with the presynaptic 
membrane for the release of neurotransmitters; a putative role in 
delivery and expression of AMPA receptors at the synapse 
5062 PAK2 Yes Yes Yes 
PAK kinases are critical effectors that link Rho GTPases to 
cytoskeleton reorganization and nuclear signaling; it was recently 
suggested that PAK2 mediates neurite outgrowth via Rac1 and 
promotes neuronal differentiation through interaction with RhoGDI1-
Rac1/Cdc42 complex [74] 
5253 PHF2 No Yes No Probable regulator of histone methyltransferase complexes 
5373 PMM2 No Yes No 
A precursor to GDP-mannose; mutations in this gene have been 
shown to cause defects in glycoprotein biosynthesis, which manifests 
as carbohydrate-deficient glycoprotein syndrome type I [75] 
10935 PRDX3 No Yes No 
Encodes a protein with antioxidant function, localized in the 
mitochondrion; involved in regulation of cellular proliferation, 
differentiation, and antioxidant functions 
5592 PRKG1 Yes Yes Yes 
Involved in mediate smooth muscle cell relaxation and vasodilation in 
responses to rises in cGMP through interaction with PPP1R12A; 
interacts with ITPR1. Mouse knockouts show subtle mental 
disabilities 
56341 PRMT8 Yes Yes Yes 
Mediates arginine methylation, a widespread posttranslational 
modification involved in many cellular processes; brain-specific 
5991 RFX3 No Yes No 
Member of regulatory factor X family; required for various 
developmental and differentiation activities 
6418 SET No Yes No 
Involved in apoptosis, transcription, nucleosome assembly and 
histone binding; stimulates DNA replication of the adenovirus 
genome complex with viral core proteins 
27352 SGSM3 Yes Yes Yes 
Plays a role in NF2-mediated growth suppression of cells; strongly 
expressed in neurons and associates with Rab proteins involved in 





GeneID Name 2A 2B Neural Documented Protein Function 
6595 SMARCA2 Yes Yes Yes 
Interacts with WINAC complex; belongs to the neural progenitors-
specific chromatin remodeling complex (npBAF complex) and the 
neuron-specific chromatin remodeling complex (nBAF complex) 
involved in neuronal development and regulation of dendrite growth 
6709 SPTAN1 Yes Yes Yes 
Is a member of a family of widely-distributed cytoskeletal proteins 
involved in actin cross-linking; potentially anchors dendritic spines to 
actin cytoskeleton and may regulate synaptogenesis and/or synaptic 
plasticity [77] 
10273 STUB1 Yes Yes Yes 
Modulates the activity of several chaperone complexes involved in 
degradation of misfolded proteins; linked to Alzheimer's disease due 
to reduction in aberrant protein scavenging causing abnormal protein 
accumulation in the brain [78] 
285362 SUMF1 No Yes No 
Catalyzes the hydrolysis of sulfate esters; mutations in this gene 
cause multiple sulfatase deficiency, a lysosomal storage disorder 
6871 TADA2A No Yes No 
Component of the ATAC complex required for the function of some 
acidic activation domains which activate transcription from a distant 
site 
9344 TAOK2 No Yes No 
Plays a role in cell signaling, microtubule organization and stability, 
and in apoptosis; Isoform1 activates the JNK MAP kinase pathway 
and binds to microtubules 
80764 THAP7 No Yes No 
Chromatin-associated protein that represses transcription via 
recruitment of HDAC3 and nuclear hormone receptor corepressors 
6434 TRA2B Yes Yes No Participates in the control of pre-mRNA splicing 
23617 TSSK2 Yes Yes No 
Involved in the late stages of spermatogenesis, during the 
reconstruction of the cytoplasm 
23331 TTC28 Yes Yes No Function is unclear 
114791 TUBGCP5 No Yes No 
Gamma-tubulin complex is necessary for microtubule nucleation at 
the centrosome 
7874 USP7 Yes Yes No 
Cleaves ubiquitin fusion protein substrates. Stabilizes TP53 and 
induces TP53-dependent cell growth repression and apoptosis; 
involved in cell proliferation during early embryonic development 
65268 WNK2 Yes Yes No 
Serine/threonine-protein kinase, and member of the WNK family; 
potentially related to cell growth or proliferation [79, 80] 
7473 WNT3 No Yes Yes 
WNT family protein, implicated in oncogenesis and in several 
developmental processes. Plays a role in cell-cell signaling during 
morphogenesis of the developing neural tube. Regulates 
neurogenesis [81] 
92822 ZNF276 No Yes No Zinc finger protein. May be involved in transcriptional regulation 
163087 ZNF383 Yes Yes No 
Zinc finger protein. May function as a transcriptional repressor for 
activities mediated by MAPK signaling pathways 
92285 ZNF585B No Yes No Zinc finger protein. May be involved in transcriptional regulation 
Table 4.3: We examined functional annotation of genes in the autism associated clusters to determine if they are 
involved in neural or brain-related functions. Table indicates which genes were present in each cluster, with cluster 
2A allowing one gene per CNV and cluster 2B allowed two genes per CNV. Also included is a short summary of gene 
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5. Diverse genetic variations in schizophrenia converge on functional gene networks  
5.1. Introduction 
The genetic causes for increased susceptibility to common complex diseases are likely to be 
numerous and varied. Schizophrenia is an example of this phenomenon; several genomic loci have been 
implicated by genome-wide association studies (GWAS) [1-4], a contribution from de novo and rare copy 
number variants (CNVs) has been established [5-7], and a significant contribution from de novo single 
nucleotide variants (SNVs) is demonstrated in a recent study based on exome sequencing in two 
populations [8]. An important challenge is to combine these diverse disease-related genetic variations 
into a single comprehensive analysis this common disorder. 
Biological networks provide an intuitively appealing framework for integration of diverse genetic 
variations [9, 10], as mutations of all types must be connected through function in order to trigger a 
single phenotype. In this chapter, we employ a modified version of our previously described algorithm in 
the analysis of existing schizophrenia variants. The new approach is able to integrate data from multiple 
types of genetic variation: SNVs, CNVs, and GWAS-implicated loci. Genes from all variants are mapped to 
the phenotype network (Figure 5.1), a greedy search algorithm identifies highly connected gene clusters 
among putative disease genes, and the significance of the cluster as a whole is established using an 
appropriate randomization. Although we and others have previously developed methods to identify and 
analyze disease-related gene networks [11-15], to our knowledge NETBAG is the first principled 
approach for integration of diverse sources of genome-wide genetic variation under a unified 
framework. The major goals for this work are: 
(1) As previously described, the method provides significance measures to a collection of disease 
genes where evaluating the significance of some individual genes may be difficult due to their 
rarity. In addition, because gene contribution to the cluster score is not uniform, we are able to 






(2) By linking genes through shared function, our method will be able to find biological functions 
behind the disorder, demonstrating that different types of mutation converge on interrelated 
molecular processes. 
 
(3) Autism was once classified as “childhood schizophrenia” and our analysis suggests that the two 
share many common biological functions. We examine how mutations in shared genes and 




Figure 5.1: The NETBAG+ algorithm. different types of genetic variations are mapped to a phenotype 
network (pale grey) where every pair of genes is assigned a score proportional to the likelihood ratio that 
those genes share a genetic phenotype. Strongly inter-connected clusters (dark grey) are identified among 
putative disease genes. Clusters scores are based on the de-weighted sum of edges between all genes in the 
cluster; this score is proportional to the likelihood that all cluster genes share the same phenotype. Cluster 






5.2.1. Gene networks from schizophrenia-associated variations 
We considered non-synonymous de novo SNVs from recent studies by Xu et al. [8] and Girard et 
al. [16], de novo CNVs from published genome-wide scans [7, 17-23] , and genomic regions implicated 
by genome-wide association studies[24-28]. In total, this set contained 1044 genes (159 from non-
synonymous de novo SNVs, 712 from de novo CNVs, 173 from GWAS) from 213 genomic locations. In 
searching for cohesive gene cluster, the algorithm was allowed to pick any gene affected by a de novo 
SNV, any gene within a de novo CNV (one gene per CNV), or any gene within a GWAS-implicated region 
(one gene per region).  
NETBAG identified a significant gene cluster (P-value < 0.001, Figure 5.2a) containing in total 47 
genes (22 from SNVs, 20 from CNVs, 6 from GWAS regions), and divided into two weakly connected sub-
clusters as marked in the figure. NETBAG was also run using different combinations of genetic variations 
(Table 5.1), but the strongest significance was achieved when all types of genetic variations were 
considered together demonstrating that different sources of genetic variations appear to reinforce each 
other increasing the overall cluster significance. While all sources contributed to the final cluster, taken 
alone SNVs and CNVs formed marginally significant clusters while GWAS did not, perhaps reflecting their 
relatively lower impact on disease risk. Despite their lack of significance alone, genes implicated through 
GWAS did improve the overall cluster significance, highlighting the fact that both common and rare 
variants may converge on shared functions. After masking the genes forming cluster I, i.e. removing 
these genes from the input data, NETBAG was able to identify another marginally significant cluster 
(Figure 5.2c, cluster II, P-value = 0.071). In contrast to these results, no significant clusters were detected 
in various control sets, for example synonymous SNVs observed in the control population, or 





Notably, taken together cluster I and cluster II included the three out of four genes (LAMA2, 
TRRAP, DPYD) with recurrent non-synonymous SNVs in the cohort analyzed by Xu et al. [8] (Fisher’s 
exact test, one-tailed, P-value = 0.05,), demonstrating that NETBAG is selecting likely causative genes. In 
addition, we performed a manual literature review of all 159 genes from Xu et al. containing a de novo 
SNV. We include brief functional descriptions for these genes with a focus on information about known 
neuronal and/or brain functions (Table 5.3). We demonstrate from this review that our clusters are 
enriched in genes with known brain and neuronal functions when compared with genes not selected by 
the algorithm. Specifically, the identified clusters contain 26 genes with known brain and neural 
functions out of 56 in total (Fisher’s exact test P-value= 10-4, Barnard’s exact test P-value=2e-5). 
 
Table 5.1: Clusters identified by the NETBAG algorithm 
Input Events Cluster size Cluster P-value 
SNVs + CNVs + GWAS 47 < 0.001 
CNVs + GWAS 29 0.013 
SNVs + CNVs 37 0.014 
SNVs 16 0.056 
CNVs 6 0.057 
Masked SNVs + CNVs + GWAS 42 0.071 
SNVs + GWAS 23 0.079 
GWAS 10 0.463 
Control SNVs 10 0.568 
Control SNVs + CNVs 18 0.572 
SNVs + CNVs + GWAS (100kb) 51 < 0.001 
SNVs + CNVs + GWAS (450kb) 48 < 0.001 
 
Table 5.1: The left column shows various combinations of input events, the middle column shows 
the number of genes in the best cluster, and the right column shows the best cluster P-value. The 
rows in the table are sorted by the P-values. “Masked” indicates an input set where the genes 
forming cluster I were removed. Control SNVs were taken from three sources: de novo mutations in 
unaffected individuals and de novo synonymous mutations in probands from the recent paper by Xu 
et al., and de novo mutations in unaffected siblings from two recent autism exome sequencing 
studies by O'Roak et al. and Sanders et al. In total, this combined set contained 161 genes. Control 
de novo CNVs were taken from unaffected siblings in a recent autism study by Levy et al., and 








Figure 5.2: Significant clusters identified using schizophrenia associated genes. (A) Cluster results from the 
combined set of schizophrenia-associated genetic variations: genes from de novo CNVs are in blue, genes from 
non-synonymous de novo SNVs are in green, and genes from GWAS-implicated regions in red. Edge width 
represents the strength of the likelihood score between two genes, and node size represents the gene’s 
contribution to the overall cluster score. For simplicity, only the top two edges from each gene are shown. Cluster I 
was the best cluster from the combined set of all schizophrenia genetic variations (P-value < 0.001). (B) The best 
cluster found when using only genes affected by non-synonymous de novo SNVs (P-value = 0.056). All genes from 
this cluster appear in the combined cluster, some with increased significance due to their connections with genes 
from other variants. (C) Cluster II was the best cluster from the combined set of all schizophrenia genetic variations 






5.2.2. Biological processes associated with schizophrenia clusters 
To determine functional roles of genes forming the identified schizophrenia clusters we used 
two computational tools (FuncAssociate [29] and DAVID [30]) which identify over-represented Gene 
Ontology (GO) terms within a given gene set. These analyses showed that the genes in cluster I 
participate in several important neurodevelopmental processes, such as axon guidance, neuron 
projection development, cell migration and locomotion (Select terms in Table 5.2, All terms in Tables 
5.4). The GO analysis also implicated several cellular pathways, including signaling through essential 
second messengers: calcium, cAMP, and inositol trisphosphate. Separate analysis of genes forming sub-
clusters Ia and Ib showed that the former was enriched for gene functions related to signaling and axon 
guidance, while the latter for functions related to neuron mobility and locomotion. The genes forming 
cluster II were enriched for functions related to chromosomal organization and chromosomal 
remodeling. Importantly, a similar GO-enrichment analysis of all genes affected by non-synonymous de 
novo SNVs or de novo CNVs did not identify any significantly enriched functional terms. Thus, the 
developed computational approach is essential for revealing cohesive functional networks hidden within 













Table 5.2a. Selected Gene Ontology (GO) terms associated with cluster I by FuncAssociate 
N X P-value GO ID GO Term 
16 326 <0.001 GO:0007411 axon guidance 
11 335 <0.001 GO:0040012 regulation of locomotion 
7 108 <0.001 GO:0000187 activation of MAPK activity 
8 193 <0.001 GO:0001666 response to hypoxia 
9 295 <0.001 GO:0030334 regulation of cell migration 
9 333 <0.001 GO:0051960 regulation of nervous system development 
8 289 0.001 GO:0019932 second-messenger-mediated signaling 
6 132 0.001 GO:0008286 insulin receptor signaling pathway 
8 307 0.001 GO:0050767 regulation of neurogenesis 
7 227 0.001 GO:0071375 cellular response to peptide hormone stimulus 
6 155 0.001 GO:0010975 regulation of neuron projection development 
7 253 0.002 GO:0045664 regulation of neuron differentiation 
3 16 0.015 GO:0035004 phosphatidylinositol 3-kinase activity 
4 54 0.018 GO:0051896 regulation of protein kinase B signaling cascade 
5 119 0.021 GO:0007204 elevation of cytosolic calcium ion concentration 
4 58 0.024 GO:0007190 activation of adenylate cyclase activity 
7 323 0.046 GO:0032870 cellular response to hormone stimulus 
6 217 0.048 GO:0048011 nerve growth factor receptor signaling pathway 
 
Table 5.2b. Selected Gene Ontology (GO) terms associated with cluster I by DAVID 
N X P-value GO ID GO Term 
7 107 8.85E-05 GO:0007411 axon guidance 
8 169 8.94E-05 GO:0030334 regulation of cell migration 
9 256 1.09E-04 GO:0031175 neuron projection development 
8 184 1.33E-04 GO:0000165 MAPKKK cascade 
8 193 1.70E-04 GO:0007409 axonogenesis 
9 339 6.14E-04 GO:0048666 neuron development 
6 96 6.47E-04 GO:0009894 regulation of catabolic process 
7 163 9.33E-04 GO:0030425 dendrite 
9 342 0.001 GO:0043005 neuron projection 
7 183 0.001 GO:0006874 cellular calcium ion homeostasis 
 
Table 5.2: Selected Gene Ontology (GO) terms associated with schizophrenia clusters. GO annotation terms that 
were over-represented among genes in cluster I (Figure 5.2a) based on the analysis with FuncAssociate and DAVID. 
In the tables N is the number of cluster genes annotated with a given GO term, and X is the total number of human 
genes with that GO annotation. Repetitive and very broad GO terms, i.e. terms associated with more than 350 
genes, are not listed in the tables. For a list of terms associated with each sub-cluster see Table 5.4. (A) The cluster-
associated GO terms identified by FuncAssociate. P-values adjusted for multiple hypothesis testing using 
simulations. (B) The cluster-associated GO terms identified by DAVID. P-values adjusted for multiple hypothesis 







5.2.3. Expression of genes from schizophrenia-associated clusters 
Complementary to curated gene ontology terms, another important descriptor of biological 
function is temporal gene expression profile. To investigate brain-related gene expression we took 
advantage of the Human Brain Transcriptome (HBT) database [31]. This database contains expression 
levels from post-mortem samples across a range of ages from subjects who were considered 
neurologically healthy. Our goal is to examine not the functioning of a schizophrenic brain, but to see 
how genes affected by the disease might function in a healthy brain. In Figure 5.3a we show the median 
brain expression profiles for the genes forming the identified clusters across 15 developmental stages 
from embryonic to late adulthood. The level of brain expression for all genes forming the identified 
clusters (orange in Figure 5.3a) is notably higher than expression of all genes in the HBT database 
(dashed grey) and all genes used as the input for NETBAG but not selected by the algorithm (dashed 
black). Moreover, the expression of the cluster genes is higher during the prenatal (left of the vertical 
dashed line) than the postnatal developmental stages. This result is in agreement with significantly 
higher enrichment for functional de novo mutations in genes biased towards prenatal expression 
observed in the recent study by Xu et al., and suggests that prenatal genetic insults are important for 
etiology of schizophrenia. 
Intriguingly, genes forming sub-cluster Ia, sub-cluster Ib, and cluster II showed distinct 
expression profiles. Sub-cluster Ia contains many genes with broad brain-related functions that are 
essential across all developmental periods; the median gene expression in this sub-cluster is quite 
uniform across considered developmental stages, and only slightly higher levels during prenatal periods. 
In contrast, genes forming cluster II are primarily responsible for chromosomal organization and 
remodeling; their expression is likely to be particularly important during periods of neuronal 
development and differentiation. Naturally, the median expression profile for the cluster II genes is 





cluster Ib also display higher prenatal expression, their median expression profile shows a prominent 
decrease between early fetal to late mid-fetal stages, approximately corresponding to the period 
between 10 and 20 post-conception weeks. Several genes (DOCK1, ITGA6, COL3A1, LAMA2, and THBS1) 
in this sub-cluster independently show U-like expression profiles (Figure 5.3b). This observation suggests 
that specific processes occurring early or late in corticogenesis may be affected in schizophrenia. 
 
 
Figure 5.3: Temporal brain expression profiles for genes forming the identified clusters. Gene expression 
profiles in the brain across developmental stages. Gene expression data were obtained from the Human Brain 
Transcriptome database (hbatlas.org). Median expression levels for each gene were quantile normalized 
values (log2 transformed) across all samples at that time point. Error bars in the figure represent standard 
error on the mean across samples, and where applicable all genes, at a given developmental stage.  (A) 
Temporal profiles of the median gene expression for the schizophrenia clusters (Figure 5.1). (B) Temporal 
expression profiles for individual genes forming sub-cluster Ib in which several genes independently exhibit U-
like expression profiles, i.e. decreased expression in early or mid-fetal development.  
 
5.2.4. Common functions between schizophrenia and autism 
Our analysis of functions underlying the schizophrenia cluster revealed many GO terms in 
common with our recent analysis of autism associated CNVs. This observation raises an intriguing 
question: how can mutations in related and overlapping genes lead to different clinical phenotypes? 





research, we decided to gain an initial insight by focusing on a distinct phenotype previously considered 
by us and others: growth of dendrites and dendritic spines. The majority of the excitatory glutamatergic 
synapses in the human brain are formed on dendritic spines, and their structural aberrations have been 
implicated in several psychiatric and neurodegenerative disorders [32, 33]. Likely impact on the growth 
of dendrites or dendritic spines by a gene within a CNV can be investigated based on the corresponding 
dosage changes, i.e. either a deletion or duplication. Using this approach we previously noted that CNVs 
associated with autism should primarily lead to an increase in spine or dendritic growth [11]. 
Interestingly, a similar analysis in schizophrenia – based on mutant phenotypes available in published 
literature for CNV-associated cluster genes (Table 5.5) – reveals the opposite trend (Figure 5.4, Fisher’s 
exact test, two-tailed, P-value = 0.01, Barnard’s exact test, two-tailed, P-value = 0.007), i.e. a majority of 
schizophrenia-associated CNVs should lead to a decrease in growth of dendrites or spines. Notably, 
postmortem brain analyses observed an increase in spine density increase in autism [34] and a decrease 
in schizophrenia [35]. Of course, morphological changes in dendritic spines are crucial to understanding 
their clinical impact. For example, it is known that in Fragile X syndrome patients had a higher density of 
dendritic spines in certain regions of the brain, but these show an immature morphology suggesting 
fewer functioning connections [36]. Thus increases and/or decreases are clearly not the only factor 
relevant to distinct clinical phenotypes. Our analysis does demonstrate, however, that different types of 








Figure 5.4: Likely impact of genes from de novo CNVs in autism and schizophrenia on growth of 
dendrites or dendritic spines. Using the dosage changes (deletion or duplication) for CNV-associated 
genes in the schizophrenia and autism clusters, we explored available literature for phenotypes 
related to growth changes of dendrites or dendritic spines. This analysis showed that while de novo 
CNVs in autism primarily lead to an increase in growth of dendrites or dendritic spines, de novo CNVs 
in schizophrenia lead to the opposite effect. The difference in the phenotypic impact for the two 
disorders was significant (Fisher’s exact test, two-tailed, P = 0.01; Barnard’s exact test, two-tailed, P = 
0.007). Genes that were considered in the analysis, their corresponding CNVs and predicted 









It is interesting to consider the implicated genes not only as a cluster in Figure 5.2, but also in 
the context of relevant signaling pathways. In figure 5.5, the genes forming the significant clusters 
identified by NETBAG are shown in yellow, other relevant genes that were present in the input data but 
not selected by the algorithm in cyan, and genes and signaling molecules previously implicated as 
playing a role in schizophrenia are circled in orange. Individual components of the presented network 
are active in diverse developmental and functional contexts, such as cell motility, axonal guidance, and 
synaptogenesis. Several conceptual signaling levels can be delineated in the network. The first layer is 
formed primarily by a diverse array of receptors and channels, ranging from receptors involved in axonal 
guidance (such as Ephrin and DCC) to ionotropic and metabotropic neurotransmitter receptors (such as 
CHRNA7 and HTR7). The second signaling layer is formed by cellular kinases, phosphatases, and GTPases 
that are, either directly or indirectly, regulated by the first signaling layer. The third layer consists of 
regulatory (such as CREB) or structural proteins (such as Cofilin) involved in neurite outgrowth, 
synaptogenesis, and synaptic plasticity. In addition to the aforementioned horizontal layers, several 
well-defined top-down pathways that were previously discussed in connection with schizophrenia and 
other brain-related diseases can be recognized [37, 38]. These include the reelin, WNT, and insulin 
signaling pathways; pathways involving Akt/PI3K, MAPK, and mTOR signaling; as well as the PKC and PKA 
pathways. Considering the remarkable diversity of the implicated molecular circuits, it is likely that many 
hundreds of genes (>1000, according to the estimate the recent study by Xu et al.) may ultimately 
contribute to the schizophrenia etiology. 
 Although genetic variations considered in this chapter differ in their type and origin, in 
combination they perturb a complex but interrelated set of molecular processes. This functional 
convergence allows the presented integrative approach to identify a cohesive functional cluster. A 





occur in many other human disorders. If this is indeed the case, it is likely that genetic data collected 
using unbiased whole-genome approaches and analyzed by proper computational methods will reveal 
the underlying molecular networks for a significant fraction of common human maladies, thus realizing 




Figure 5.5: Genes forming the NETBAG clusters in the context of cellular signaling pathways. Proteins encoded by 
cluster genes (Figure 5.2) are shown in yellow, and those corresponding to other relevant genes that were present 
in the input data but not selected by the NETBAG algorithm are shown in cyan. Proteins and signaling molecules 
that were previously implicated in schizophrenia are circled in red. ER, endoplasmic reticulum; IP3, inositol-1,4,5-








Schizophrenia-associated genetic variation  
We used three types of genetic variation: 159 non-synonymous de novo SNVs from two recent 
studies by Xu et al. and Girard et al., de novo CNVs from several previous studies, and 14 genomic 
regions that were implicated by SNPs (P-value < 5e-8) in recent genome-wide association studies. We 
considered all genes affected by non-synonymous de novo SNVs, all genes that overlap the de novo 
CNVs events according to the human genome NCBI build 36, and – following previous studies – all genes 
overlapping a region 250 kb in either direction from SNPs implicated by GWAS; similar results were 
obtained using calculations with distances of 100 kb and 450 kb from GWAS-implicates SNPs (Table 5.1). 
In total, our set contained 1044 genes from 213 genomic regions: 159 from SNVs, 712 from CNVs, and 
173 from genomic loci implicated by GWAS. 
 
NETBAG Algorithm 
Genes affected by the considered genetic variations were mapped to the phenotype network 
where every gene pair is connected by a score representing the likelihood that those genes contribute 
to a shared phenotype. NETBAG employs a greedy algorithm previously described to find the highest 
scoring cluster at each size. Cluster score is the sum of contributions from each gene, and each gene 
contributes based on a de-weighted sum of the edges between it and other cluster genes. De-weighting, 
in which the sum is the strongest edge plus half of the second strongest edge, plus one third of the third 
strongest edge and so on, reflects our belief that because all cluster genes share common functions their 
edges are not wholly independent. Cluster significance was determined based on a distribution of 
cluster scores obtained by applying the same greedy search algorithm to randomized data. The cluster 
size with the strongest significance is selected and the P-value is adjusted for multiple hypothesis 





To generate random datasets, we selected genes with average connection strengths in the 
phenotype network comparable to the disease-associated input genes. This ensures that it is not high 
overall connectivity of potential disease genes that drives cluster significance. The average connection 
strength was calculated by considering the weights of the 20 strongest edges from a particular gene to 
all other network genes.  
For a disease cluster of a given size, we assigned a size-specific P-value based on randomized 
clusters of the same size. To correct for multiple hypothesis testing (due to considering clusters at 
multiple sizes), we took the best P-value from each random trial regardless of cluster size and used this 
distribution to assign a P-value to the size-specific P-value. Throughout the paper we used this corrected 
P-value to characterize cluster significances. We ignored clusters with five genes or less to ensure that 
our analysis is not overly influenced by very small gene clusters with strong connections.  
In this analysis we found that many clusters shared the same, highly significant P-values. We 
therefore defined a z-score for each cluster based on scores from clusters of the same size found using 
random events and selected the final cluster based on a combination of P-value and z-score.  
 
Cluster functional analysis 
To establish specific biological functions associated with the schizophrenia clusters, we used two 
computational tools, FuncAssociate and DAVID, to find all over-represented GO terms. For clarity, we 
show only the terms with fewer than 350 associated human genes. In the tables we report only multiple 
hypothesis corrected P-values. 
 
Brain expression profiles  
To examine the expression of cluster genes across developmental stages, we used expression 





Transcriptome database (http://hbatlas.org/). Median expression levels for each gene were quantile 
normalized values and log2-transformed across all samples. The database contained samples across a 
range of developmental stages including: embryonic, early/mid/late fetal, neonatal/early/late infancy, 
early/middle/late childhood, adolescence, and young/middle/late adulthood. This dataset allowed us to 
analyze what functions in a healthy human brain might be compromised by these mutations.  
 
Likely impact of CNV events on dendrites and dendritic spines 
To assess the impact of cluster genes associated with de novo CNVs on the growth of dendrites 
and dendritic spines, we performed an analysis of available literature. CNV polarity, i.e. deletion or 
duplication, allowed us to determine a corresponding change in gene dosage. CNV-associated genes 
were taken from either the schizophrenia clusters or the autism cluster identified in our previous work. 
For the two genes with both duplication and deletion events (CRKL and PIAS3), we used the frequency of 
CNVs reported in Malhotra et al. [5] to determine the predominant polarity associated with each 
disease. The information about CNV-associated genes, polarities, and phenotypes reported in the 







Table 5.3: Literature review of SNV genes 




Membrane transport molecule. Linked to cholesterol transport and 









Protein encoded is the major procollagen II N-propeptidase. Family members 
linked to diabetes and defects in connective tissue. (21822266) 
ADCY7 I Yes 
Membrane bound catalyst inhibited by calcium, found in neurons, and part of 
cAMP pathway. (17135423, 21822266, 20299190) 
AHNAK2 
 




Acts as a guanine nucleotide exchange factor (GEF) for Rab5 GTPase. Involved in 








AP-2 seems to play a role in the recycling of synaptic  vesicle membranes from 












Transcriptional corepressor. May specifically inhibit gene expression when 





This protein inhibits apoptosis by facilitating the degradation of apoptotic 
proteins by ubiquitination. 
BRPF1 II Yes 
Positively regulates the transcription of RUNX1 and RUNX2. Potentially required 
for maintenance of cranial Hox gene expression. (18469222) 
C16orf62 
 












C2cd3 is required for cilia formation and is a recessive lethal mouse mutant with 
multiple defects, including neural tube defects. (19004860) 
CAMK4 I Yes 
May play a role in the consolidation/retention of hippocampus-dependent long-




Calcium-binding protein that interacts with newly synthesized glycoproteins in 
the endoplasmic reticulum. 
CARD6 
 








No Little information. (21822266) 
CCDC137 
 




CCDC39 is required for assembly of inner dynein arms and the dynein regulatory 
complex and for normal ciliary motility in humans(21131972) 
CCDC84 
 
No Little information. 
CEACAM18 
 
No Little information. 
CHD4 II Yes 
Main component of the nucleosome remodeling and deacetylase complex and 
plays an important role in epigenetic transcriptional repression. 
CIT I Yes 
 Plays an important role in the regulation of cytokinesis and the development of 




Required for the development and/or maintenance of the proper glomerular 
endothelial cell and podocyte architecture.  
COL3A1 I Yes 
 Collagen type III occurs in most soft connective tissues along with type I 










Conserved in multicellular eukaryotic organisms, functions in the nucleus by 








No Promotes the activation of ARF through replacement of GDP with GTP. 
DAB2IP 
 




May be involved in the maintenance of the endoplasmic reticulum and/or Golgi 
structures. (22037555) 
DDX10 II No 
May be involved in ribosome assembly. Family members believed to be involved 




Encodes a novel putative adhesion receptor protein, which could play a role in 
neural crest cells migration, a process which has been proposed to be altered in 
DiGeorge syndrome (16783572) 
DHX8 II No 
Facilitates nuclear export of spliced mRNA by releasing the RNA from the 
spliceosome. 
DOCK1 I Yes 
Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic 
cells and cell motility. Dock3 stimulates axon outgrowth (22219288)  
DPYD II Yes 
Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and 




Plays a role in spinal chord development, guiding commissural axons projection 
and path finding across the ventral midline. 
EDEM2 
 
No Degrades mis-folded proteins in a process known as ER-associated degradation 








No Little information. 
EVC2 
 
No Plays a critical role in bone formation and skeletal development. 
FAM13C 
 
No Little information. 
FAM3D 
 
No Little information. 
FASTKD5 
 
No Kinase protein involved in apoptosis. 
FBXO7 II Yes 
Component of a complex which mediates the ubiquitination and subsequent 
proteasomal degradation of target proteins. Mutations associated with 




May be involved in the maintenance of the mucosal structure as a gel-like 




Glycoprotein secreted by parietal cells of the gastric mucosa and is required for 




Guanine nucleotide-binding proteins (G proteins) are involved as modulators or 
transducers in various transmembrane signaling systems. (14741323) 
GPR115 
 
No Little information. 
GPR153 
 
No Little information. 
GPRIN3 
 




 Variant histone H2A which replaces conventional H2A in a subset of 
nucleosomes. May be involved in the formation of constitutive heterochromatin, 




Probable E3 ubiquitin-protein ligase. May be required for development of the 




Encodes a member of the histone H1 family. Found in the large histone gene 
cluster on chromosome 6. 
HLA-C 
 
No Major histocompatibility complex. 
HLA-DQA1 
 
No Major histocompatibility complex. 
HMGCR 
 






Gene Cluster Neural Function 
HTR7 I Yes 
Serotonin receptor belonging to the superfamily of G protein-coupled receptors. 
A candidate locus for involvement in autistic disorder and other neuropsychiatric 
disorders. (16192982, 10490701) 
IFT140 
 
No Little information. 
IFT81 
 




Family of signaling molecules that play critical roles in cellular energy 




Mobilizes intracellular calcium and acts as a second messenger mediating cell 




Subunit of the Integrator complex, which mediates 3-prime end processing of 
small nuclear RNAs. 
IRS1 I Yes 
Phosphorylated by insulin receptor tyrosine kinase. Mutations in this gene are 
associated with type II diabetes and susceptibility to insulin resistance. 
ITGA6 I Yes 
Integrins are known to participate in cell adhesion as well as cell-surface 
mediated signaling. a receptor forlaminin in epithelial cells and it plays a critical 




F-box proteins function in phosphorylation-dependent ubiquitination, deficiency 
leads to neural progenitor death. (21220025) 
KDM5C II Yes 
Participates in transcriptional repression of neuronal genes by recruiting histone 




May be involved in superoxide dismutase activity and in neuroprotective effect 
of peroxisomes, May enhance epileptogenesis and confer low seizure threshold. 
KIAA1109 
 
No Membrane gene, involved in rheumatoid arthritis. 
KLF12 II No 
Developmentally-regulated transcription factor and important regulator of gene 
expression during vertebrate development and carcinogenesis. 




Co-expressed during differentiation of simple and stratified epithelial tissues, 
specifically expressed in differentiated layers of the mucosal and esophageal 
epithelia.  
LAMA1 I Yes 
Mediates attachment, migration and organization of cells into tissues during 
embryonic development. (21743468, 18369103) 
LAMA2 I Yes 








Integral to plasma membrane and has both phlorizin hydrolase activity and 
lactase activity. 
LRP1 I Yes 
Required for early embryonic development. Involved in cellular lipid 












Sterol-regulated subtilisin-like serine protease involved in regulation of lipid 
metabolism in cells. 
MTOR I Yes 
Central regulator of cellular metabolism, growth and survival in response to 




Mucins are high molecular mass, highly glycosylated macromolecules that are 
the major components of mucus secretions 
MYH10 I Yes 
Large family of motor proteins. Appears to play a role in cytokinesis, cell shape, 









May act as a tumor suppressor. Suppresses cell growth and enhanced sensitivity 
to various anticancer drug. 





Gene Cluster Neural Function 
NUP54 II No 
Component of the nuclear pore complex, a complex required for the trafficking 




Olfactory receptors interact with odorant molecules in the nose, to initiate a 
neuronal response that triggers the perception of a smell. 
P2RY2 I No 
Receptor responsive to both adenosine and uridine nucleotides; may participate 




Inhibits immunological synapse formation by preventing dynamic arrangement 




Cleaves insulin-like growth factor-binding protein 5; thought to be a local 
regulator of insulin-like growth factor. 
PHF23 
 
No Little information. 
PIK3CB I Yes 
Participates in signaling pathway coordinating a diverse range of cell functions 
including proliferation, cell survival, degranulation, vesicular trafficking and cell 




Regulates RHOA activity, and plays a role in cytoskeleton remodeling. Necessary 




Member of phospholipase family ubiquitously expressed with diverse biological 
functions including inflammation, cell growth, signaling and death and 
maintenance of membrane phospholipids. 
PLCL2 
 
No Little information 
PLK3 I Yes 
Regulator involved in stress response, cell cycle progression, mitosis, cytokinesis, 
and the DNA damage response. Expression in rat brain associated with synaptic 
plasticity. (15640841) 
PML I Yes 
Regulates a large number of cellular processes. Required for normal immunity to 





Creates a molecular switch for regulating the phosphorylation status of PPP1CA 




May play a role in the regulation of phospholipid turnover as well as in 
protection against oxidative injury. Differentially expressed in schizophrenic 
brains. (19405953) 
PRKCB I Yes 
 Calcium-activated, phospholipid involved in various cellular processes including 
regulation of gene expression and control of cell division and differentiation. 




Pregnancy-specific glycoproteins (PSGs), released into the maternal circulation 
during pregnancy.  
PTPRM I Yes 
May play a key role in signal transduction and growth control. Component of 
developmental pathways important in schizophrenia. (18369103) 
RARG 
 




Activates the Erk/MAP kinase cascade and regulates T-cells and B-cells 
development, homeostasis and differentiation. Enriched in brain and potentially 
linked to BDNF signaling. (17453053) 
RB1CC1 
 









Required for the biogenesis of motile cilia by governing growth and beating 
efficiency of motile cells. Implicated in developmental conditions and 









Plays a role in regulation of ribosome production in response to cellular stress 























May be involved in actively transporting phosphate into cells via Na(+) co-




High-affinity transporter for the intake of thiamine. Mutations in this gene cause 












May play a role in clathrin-dependent retrograde transport from early 




Plays a role in the maintenance of X-inactivation and the hypermethylation of 
CpG islands associated with inactive X. 
SPATA22 
 
No Little information. Associated with spermatogenesis. 
SPATA5 
 
No Little information. Associated with spermatogenesis. 
SPIB II No 
May be required for B-cell receptor (BCR) signaling, which is necessary for 




May be involved in transcription regulation of the alpha 2(I) collagen gene 
(COL1A2) associated with disease of connective tissue and bones. 
STAC2 
 




Component of cohesin complex, a complex required for the cohesion of sister 




May play a regulatory role in the acute-phase response in systemic inflammation 




Major constituent of the post-synaptic density. Mutations associated with 




Type-VI intermediate filament (IF) which plays an important role within the 
muscle cell cytoskeleton. 
TAF7L II No 




No May act as a GTPase-activating protein for Rab family proteins. 
TEKT5 
 
No Forms filamentous polymers in the walls of ciliary and flagellar microtubules.  
TEP1 II Yes 
Component of the complex responsible for telomerase activity. Potentially 




 Catalyzes the cross-linking of proteins and the conjugation of polyamines to 
proteins (by similarity). 
THBS1 I Yes 
Adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. 
Potentially linked to the Reelin pathway and neuronal migration and 




DNA topoisomerase, an enzyme that controls and alters the topologic states of 
DNA during transcription.  
TRAK1 II Yes 
Involved in the regulation of trafficking of EGF-EGFR complexes and GABA-A 
receptors important in developmental of hippocampal neurons and linked to 




Membrane protein that may be involved in chronic inflammation by triggering 
the production of constitutive inflammatory cytokines. Potentially important in 
microglia function. (15686960) 
TRRAP I No 
Adapter protein, which is found in various multi-protein chromatin complexes 
with histone acetyltransferase activity (HAT), which gives a specific tag for 




A membrane-bound transcription regulator that translocates to the nucleus in 










Ubiquilin thought to functionally link the ubiquitination machinery to the 
proteasome to affect in vivo protein degradation. Family members associated 
with ALS and dementia. (21857683) 
UBR5 I No 
Recognizes and binds to proteins bearing specific amino-terminal residues 




Important in the conjugation and subsequent elimination of potentially toxic 




Probably plays a role in vesicle maturation during exocytosis. Probably is 
involved in neurotransmitter release. 
URB2 
 
No Little information. 
VN1R4 
 




Component of the retromer complex, regulates transcytosis of the polymeric 
immunoglobulin receptor. Might regulate levels of the Aβ peptide in Alzheimer 




May act as an adaptor protein that modulates the transforming growth factor-
beta response by coupling the transforming growth factor-beta receptor 




Members of this family are involved in a variety of cellular processes, including 
cell cycle progression, signal transduction, apoptosis, and gene regulation. 
XPR1 
  
Potential receptor for xenotropic andpolytropic murine leukemia retroviruses. 
ZBTB40 
 
No Little information. 
ZNF229 II No Little information. 
ZNF480 II No 
Positive regulator in MAPK-mediated signaling pathways that lead to the 
activation of AP-1 and SRE important for human heart development. 
ZNF530 
 
No Little information. 
ZNF565 II No Little information. 
Table 5.3: We performed a manual literature review of information for the 159 genes with de novo SNVs from 
the recent study by Xu et al. In the table we indicate whether each gene is a member of the cluster I or II (Figure 
5.2), and whether the gene has a known neural or brain-related function. Functional descriptions in the table 







Table 5.4: All Gene Ontology (GO) terms associated with schizophrenia clusters 
Cluster Ia terms from FuncAssociate 
N X P-value GO ID GO Term 
12 326 <0.001 GO:0007411 axon guidance 
10 324 <0.001 GO:0033674 positive regulation of kinase activity 
10 334 <0.001 GO:0051347 positive regulation of transferase activity 
8 193 <0.001 GO:0006874 cellular calcium ion homeostasis 
8 198 <0.001 GO:0072503 cellular divalent inorganic cation homeostasis 
8 202 <0.001 GO:0055074 calcium ion homeostasis 
8 208 <0.001 GO:0072507 divalent inorganic cation homeostasis 
9 310 <0.001 GO:0045860 positive regulation of protein kinase activity 
8 265 0.001 GO:0006875 cellular metal ion homeostasis 
6 108 0.001 GO:0000187 activation of MAPK activity 
8 277 0.001 GO:0055065 metal ion homeostasis 
7 193 0.001 GO:0001666 response to hypoxia 
8 289 0.001 GO:0019932 second-messenger-mediated signaling 
8 293 0.001 GO:0030003 cellular cation homeostasis 
7 209 0.001 GO:0070482 response to oxygen levels 
6 132 0.001 GO:0008286 insulin receptor signaling pathway 
8 333 0.001 GO:0051960 regulation of nervous system development 
7 227 0.001 GO:0071375 cellular response to peptide hormone stimulus 
8 337 0.001 GO:0055080 cation homeostasis 
6 147 0.001 GO:0043406 positive regulation of MAP kinase activity 
8 349 0.001 GO:0030030 cell projection organization 
6 151 0.001 GO:0010638 positive regulation of organelle organization 
6 151 0.001 GO:0045121 membrane raft 
3 10 0.001 GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity 
5 89 0.001 GO:0043900 regulation of multi-organism process 
7 264 0.001 GO:0019901 protein kinase binding 
6 174 0.001 GO:0032869 cellular response to insulin stimulus 
6 178 0.001 GO:0071902 
positive regulation of protein serine/threonine kinase 
activity 
5 101 0.001 GO:0031346 positive regulation of cell projection organization 
6 188 0.002 GO:0031344 regulation of cell projection organization 
2 2 0.008 GO:0005899 insulin receptor complex 
7 307 0.008 GO:0019900 kinase binding 
7 307 0.008 GO:0050767 regulation of neurogenesis 
6 200 0.008 GO:0043405 regulation of MAP kinase activity 
3 16 0.008 GO:0035004 phosphatidylinositol 3-kinase activity 
4 53 0.008 GO:0045995 regulation of embryonic development 
3 17 0.011 GO:0034504 protein localization to nucleus 
4 55 0.011 GO:0009895 negative regulation of catabolic process 
5 119 0.011 GO:0007204 elevation of cytosolic calcium ion concentration 
7 323 0.011 GO:0032870 cellular response to hormone stimulus 
4 58 0.011 GO:0007190 activation of adenylate cyclase activity 
6 217 0.011 GO:0048011 nerve growth factor receptor signaling pathway 
5 126 0.011 GO:0046777 protein autophosphorylation 
4 59 0.011 GO:0045762 positive regulation of adenylate cyclase activity 
7 335 0.011 GO:0040012 regulation of locomotion 





Cluster Ia terms from FuncAssociate 
N X P-value GO ID GO Term 
4 60 0.011 GO:0031281 positive regulation of cyclase activity 
7 339 0.011 GO:0043434 response to peptide hormone stimulus 
6 225 0.012 GO:0032868 response to insulin stimulus 
4 62 0.012 GO:0051349 positive regulation of lyase activity 
7 345 0.012 GO:0031401 positive regulation of protein modification process 
6 228 0.012 GO:0010562 positive regulation of phosphorus metabolic process 
6 228 0.012 GO:0045937 positive regulation of phosphate metabolic process 
5 134 0.012 GO:0051480 cytosolic calcium ion homeostasis 
4 65 0.012 GO:0007163 establishment or maintenance of cell polarity 
5 140 0.027 GO:0032386 regulation of intracellular transport 
3 22 0.028 GO:0005979 regulation of glycogen biosynthetic process 
3 22 0.028 GO:0010962 regulation of glucan biosynthetic process 
3 22 0.028 GO:0032885 regulation of polysaccharide biosynthetic process 
6 241 0.028 GO:0032269 negative regulation of cellular protein metabolic process 
5 145 0.029 GO:0032147 activation of protein kinase activity 
6 253 0.031 GO:0045664 regulation of neuron differentiation 
3 25 0.033 GO:0032881 regulation of polysaccharide metabolic process 
3 25 0.033 GO:0070873 regulation of glycogen metabolic process 
5 155 0.033 GO:0010975 regulation of neuron projection development 
4 76 0.033 GO:0008543 fibroblast growth factor receptor signaling pathway 
 Cluster Ib terms from FuncAssociate 
N X P-value GO ID GO Term 
3 61 0.001 GO:0007229 integrin-mediated signaling pathway 
2 7 0.002 GO:0005606 laminin-1 complex 
4 326 0.002 GO:0007411 axon guidance 
4 332 0.002 GO:0051270 regulation of cellular component movement 
4 335 0.002 GO:0040012 regulation of locomotion 
2 9 0.002 GO:0006911 phagocytosis, engulfment 
2 9 0.002 GO:0043256 laminin complex 
2 14 0.01 GO:0043394 proteoglycan binding 
3 169 0.026 GO:0044420 extracellular matrix part 
2 27 0.039 GO:0018149 peptide cross-linking 
3 197 0.039 GO:0030155 regulation of cell adhesion 
 Cluster II terms from FuncAssociate 
N X Padj-value GO ID GO Term 
7 137 <0.001 GO:0004386 helicase activity 
6 101 <0.001 GO:0008026 ATP-dependent helicase activity 
6 101 <0.001 GO:0070035 purine NTP-dependent helicase activity 
7 252 0.002 GO:0042623 ATPase activity, coupled 
7 309 0.025 GO:0016887 ATPase activity 





Cluster Ia terms from DAVID 
N X P-value GO ID GO Term 
10 345 4.90E-05 GO:0045859 regulation of protein kinase activity 
6 61 7.54E-05 GO:0031329 regulation of cellular catabolic process 
8 209 1.56E-04 GO:0048667 cell morphogenesis involved in neuron differentiation 
8 213 1.65E-04 GO:0048812 neuron projection morphogenesis 
8 231 2.67E-04 GO:0033674 positive regulation of kinase activity 
8 240 3.24E-04 GO:0051347 positive regulation of transferase activity 
8 245 3.34E-04 GO:0048858 cell projection morphogenesis 
8 244 3.42E-04 GO:0000904 cell morphogenesis involved in differentiation 
8 256 4.25E-04 GO:0031175 neuron projection development 
8 256 4.25E-04 GO:0032990 cell part morphogenesis 
6 96 4.26E-04 GO:0009894 regulation of catabolic process 
7 163 5.06E-04 GO:0030425 dendrite 
7 184 5.90E-04 GO:0000165 MAPKKK cascade 
6 107 6.12E-04 GO:0007411 axon guidance 
7 183 6.18E-04 GO:0006874 cellular calcium ion homeostasis 
7 188 6.43E-04 GO:0055074 calcium ion homeostasis 
7 193 7.20E-04 GO:0007409 axonogenesis 
9 342 7.30E-04 GO:0043005 neuron projection 
7 196 7.60E-04 GO:0006875 cellular metal ion homeostasis 
7 205 9.48E-04 GO:0055065 metal ion homeostasis 
6 143 0.001 GO:0045121 membrane raft 
7 223 0.001 GO:0045860 positive regulation of protein kinase activity 
7 227 0.002 GO:0030005 cellular di-, tri-valent inorganic cation homeostasis 
8 339 0.002 GO:0048666 neuron development 
7 239 0.002 GO:0055066 di-, tri-valent inorganic cation homeostasis 
7 254 0.003 GO:0030003 cellular cation homeostasis 
5 82 0.003 GO:0000187 activation of MAPK activity 
7 286 0.004 GO:0055080 cation homeostasis 
4 37 0.005 GO:0009895 negative regulation of catabolic process 
7 295 0.005 GO:0009967 positive regulation of signal transduction 
5 102 0.005 GO:0043406 positive regulation of MAP kinase activity 
7 329 0.008 GO:0010647 positive regulation of cell communication 
4 55 0.012 GO:0007190 activation of adenylate cyclase activity 
4 56 0.012 GO:0045762 positive regulation of adenylate cyclase activity 
4 57 0.013 GO:0031281 positive regulation of cyclase activity 
5 134 0.013 GO:0001666 response to hypoxia 
4 59 0.013 GO:0051349 positive regulation of lyase activity 
5 141 0.014 GO:0070482 response to oxygen levels 
5 141 0.014 GO:0043405 regulation of MAP kinase activity 
3 14 0.014 GO:0032885 regulation of polysaccharide biosynthetic process 
3 14 0.014 GO:0010962 regulation of glucan biosynthetic process 
3 14 0.014 GO:0005979 regulation of glycogen biosynthetic process 
3 15 0.016 GO:0032881 regulation of polysaccharide metabolic process 
5 147 0.017 GO:0019901 protein kinase binding 
5 168 0.021 GO:0043025 cell soma 
6 276 0.021 GO:0016477 cell migration 
5 169 0.026 GO:0030334 regulation of cell migration 





Cluster Ia terms from DAVID 
N X P-value GO ID GO Term 
3 20 0.027 GO:0031330 negative regulation of cellular catabolic process 
3 21 0.029 GO:0043255 regulation of carbohydrate biosynthetic process 
6 307 0.030 GO:0048870 cell motility 
6 307 0.030 GO:0051674 localization of cell 
4 83 0.030 GO:0010638 positive regulation of organelle organization 
5 181 0.030 GO:0051130 positive regulation of cellular component organization 
5 180 0.030 GO:0032269 negative regulation of cellular protein metabolic process 
5 179 0.030 GO:0019900 kinase binding 
4 85 0.030 GO:0046777 protein amino acid autophosphorylation 
5 187 0.032 GO:0031401 positive regulation of protein modification process 
5 187 0.032 GO:0051248 negative regulation of protein metabolic process 
5 192 0.035 GO:0040012 regulation of locomotion 
5 193 0.035 GO:0051270 regulation of cell motion 
3 26 0.039 GO:0050994 regulation of lipid catabolic process 
4 96 0.040 GO:0045761 regulation of adenylate cyclase activity 
4 99 0.043 GO:0031279 regulation of cyclase activity 
4 100 0.043 GO:0048585 negative regulation of response to stimulus 
3 28 0.043 GO:0046320 regulation of fatty acid oxidation 
6 342 0.043 GO:0007167 enzyme linked receptor protein signaling pathway 
4 101 0.044 GO:0030817 regulation of cAMP biosynthetic process 
4 101 0.044 GO:0051339 regulation of lyase activity 
4 103 0.045 GO:0030814 regulation of cAMP metabolic process 
5 215 0.046 GO:0007507 heart development 
3 30 0.046 GO:0043467 
regulation of generation of precursor metabolites and 
energy 
4 107 0.049 GO:0043010 camera-type eye development 
 Cluster Ib terms from DAVID 
N X P-value GO ID GO Term 
4 345 0.004 GO:0031012 extracellular matrix 
4 137 0.006 GO:0030155 regulation of cell adhesion 
3 117 0.012 GO:0044420 extracellular matrix part 
3 59 0.012 GO:0005178 integrin binding 
2 7 0.024 GO:0005606 laminin-1 complex 
2 9 0.025 GO:0043256 laminin complex 
3 70 0.029 GO:0007229 integrin-mediated signaling pathway 
2 17 0.036 GO:0005605 basal lamina 
3 320 0.037 GO:0005578 proteinaceous extracellular matrix 
3 196 0.043 GO:0032403 protein complex binding 
2 11 0.050 GO:0043236 laminin binding 





Cluster II terms from DAVID 
N X P-value GO ID GO Term 
8 140 3.03E-05 GO:0004386 helicase activity 
6 98 8.85E-04 GO:0008026 ATP-dependent helicase activity 
6 98 8.85E-04 GO:0070035 purine NTP-dependent helicase activity 
8 274 0.002 GO:0016568 chromatin modification 
7 272 0.006 GO:0042623 ATPase activity, coupled 
4 71 0.008 GO:0016585 chromatin remodeling complex 
7 334 0.013 GO:0016887 ATPase activity 
Table 5.4: We searched for over-represented GO terms describing the schizophrenia clusters in Figure 5.1. In the 
table, N is the number of cluster genes annotated with a given term, X is the number of all human genes with that 
GO term. All P-values have been corrected for multiple hypothesis testing based on the number of considered GO 
terms. For FuncAssociate, correction was done through randomized simulations. For DAVID, correction was done 









Table 5.5: Likely impact of CNVs on the growth of dendrites and dendritic spines 










A negative regulator promoting the phosphorylation and destruction of β-catenin 






Knockdown of BAIAP2 through RNA reduces the density, length and width of 
dendritic spines (15673667); overexpression of IRSp53 in cultured hippocampal 
neurons can increase spine density, whereas RNAi knockdown of IRSp53 protein 






CAP1 promotes actin dynamics, with depletion of CAP1 leading to cofilin-1 
improperly localized (15004221), while reduction in cofilin-1 expression exhibited 





CAP2 less well studied but 64% amino acid identity to CAP1 (8761950) and 
potentially linked function (11919151); CAP2Δ mutations may cause defects in 
capping filament barbed ends (14680631) Dupl 
 
Dec 





Reduction of CRKL block dendrogensis (18477607); deletions in SCZ versus ASD, 
4:1; duplications in ASD versus SCZ, 9:19  Del Dupl Dec Inc 
CTNNA3 
Alpha-catenin regulates actin-filament assembly, potentially through competition 


















PDZ (PSD-95/Dlg/ZO-1) scaffold interacts with and promotes actin nucleation on 





Mice lacking DVL1 had reduced dendritic arborization in hippocampal neurons 
(15608632) ; DVL1 is a core component of Wnt7a, which increases the density and 
maturity of dendritic spines (21670302) Del 
 
Dec 






FLNA is an actin-binding protein that crosslinks filaments, which is necessary for 






Results suggest that IRs stimulate the growth rate of dendrites and prevent light-
induced dendritic plasticity (18549776); overexpression of IRSp53 in cultured 
hippocampal neurons can increase spine density, whereas RNAi knockdown of 





LIMK1 deficits result in decreased number of dendritic spines or abnormally small, 
thin spines (15184030, 20203211) 
Dupl / 
Del Dupl Inc / Dec Inc 
MAPT 
Overexpression of Tau leads to decreased levels of β-catenin46, which is necessary 











Pak2 phosphorylates LIMK1, inactivating cofilin which increases growth (DOI: 
10.1007/978-1-4419-7368-9_11) Del Del Dec Dec 
PIAS3 
PIASx, as a MEF2 SUMO E3 ligase, promotes dendritic claw differentiation in the 











Table 5.5: We performed a literature review to assess the impact of cluster genes associated with de novo CNVs on the 
growth of dendrites and dendritic spines – increase (inc) or decrease (dec). CNV polarity, i.e. deletion (del) or duplication 
(dupl), allowed us to determine a corresponding change in the gene dosage. CNV-associated genes were taken from either 
the schizophrenia clusters or the autism cluster identified in our previous work. For the two genes with both duplication and 
deletion events (CRKL and PIAS3), we used the frequency of CNVs reported in Malhotra et al. to determine the predominant 
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6. Function and phenotype across de novo genetic mutations associated with autism 
6.1. Introduction 
 The list of genes affecting an individual’s susceptibility to autism is rapidly growing; recent 
studies have implicated many causal genes and it is estimated that hundreds more may contribute to 
disease risk [1]. Studies focusing on de novo events have been particularly successful as these mutations 
provide a mechanism by which cases may continue to arise even for a disease like autism with a strong 
negative impact on fecundity [2-7]. With this data has come a new understanding of the biological 
pathways unifying disease genes and the impact these have on pathophysiology, an understanding 
crucial to developing better diagnostic tests and uncovering new therapeutic interventions [8-10]. The 
next step in the study of ASD is to use this biological knowledge to better describe the phenotypes 
represented by the disorder as autism is associated with particularly wide range of cognitive and 
behavioral symptoms [4, 10, 11].  
In this chapter, we employ our method, NETBAG, to integrate copy number variants (CNVs) and 
single nucleotide variants (SNVs) from several recent studies of the SSC collection [3-6]. Our method 
searches a diverse collection of disease-linked genetic variants for gene clusters with high functional 
similarity, utilizing the fact that true causal mutations will share common molecular mechanisms [12]. 
We find these mutations converge on a several processes relevant to ASD: signaling at the post synaptic 
density, neuronal growth particularly of dendritic spines, and DNA modification. 
We take this analysis further, leveraging the data from two large scale projects. First and 
foremost, the Simons Simplex Collection (SSC) [13] is a pioneering effort to collect a comprehensive 
array of genetic and phenotypic data for ASD subjects, including assessment scores measuring 
intelligence and social responsiveness. Second, the Human Brain Transcriptome has produced to large 
collection gene expression microarray data covering multiple healthy individuals over a range of 





for a more detailed study of the impact of certain genes on neuronal development. We explore 
expression profiles for functional subsets across multiple brain regions and developmental stages, and 
across phenotype scores collected in the SSC to better understand the connections between mutation, 
function, and phenotype.    
 The major goals of this chapter are:  
 
(1) Expand on our previous analysis of de novo CNVs associated with autism by integrating de novo 
SNVs. We show that these different types of mutation form an integrated cluster representing 
multiple functions relevant to the disease. In addition, there has been a focus on truncating 
mutations – such as nonsense, splice site, and frameshift mutations – which are more disruptive 
of protein function. These mutations occur more frequently in autistic subjects than their 
unaffected siblings making them likely causative [3]. We show, however, that non-truncating 
mutations are also crucial to the disease cluster. 
 
(2) We find interesting distinct expression patterns for ASD variants based on mutation type, 
function, and phenotype values such as subject sex and disease severity, mirroring the 
heterogeneous nature of ASD phenotypes.  
 
(3) Finally, we show that for some phenotypic measurements relate to gene contribution to the 
NETBAG cluster, suggesting that in the future the functional relevance of individual mutations 








6.2.1. Gene cluster affected by de novo mutations  
To elucidate the molecular networks underlying ASD, NETBAG was applied to a collection of 
genes affected by non-synonymous de novo CNVs and SNVs observed in autistic patients in the Simons 
Simplex Collection (SSC) [3-6]. The combined data from four recent studies collectively identified 985 
unique genes at 619 genomic locations. Our method searched for a subset of these genes that are 
strongly connected in an underlying phenotype network, where every gene pair is connected by a score 
proportional to the likelihood that contribute to a shared disease. This search revealed a highly 
significant cluster containing 157 genes (P-value=0.007, Figure 6.1). Notably, every study contributed a 
number of genes to the identified cluster highlighting the importance of aggregating genetic variants 
and variant types (31/157 genes from CNVs in Levy et al. and 129/157 genes were from SNVs; 51 from 
O’Roak et al., 54 from Iossifov et al., and 31 from Sanders et al.). In addition, the cluster obtained using 
all data was more significant than any of the clusters found using a single study (Table 6.1), and no 
significant clusters were found among the non-synonymous de novo variants identified in unaffected 
siblings from these studies.  
As validation that NETBAG is preferentially selecting causative mutations, we consider gene 
recurrence and haploinsufficiency. Over the three studies of SNVs, recurrent truncating mutations were 
reported for four genes (KATNAL2, CHD8, DYRK1A, and SCN2A), making them likely causative genes [3, 
15]. Three of these genes were selected by NETBAG, although only 23% (129/574) of all SNV-implicated 
genes were selected (Fisher’s exact test, two-tail P-value = 0.037). In addition, as all of the de novo 
variants were reportedly heterozygous, true causative mutations are more likely to occur in 
haploinsufficient genes. Using predicted probabilities from a recent study [16], we found that genes in 
our cluster are significantly more likely to be haploinsufficient than the remaining implicated genes 





< 1e-20). Results were comparable even when considering only SNV-implicated genes. In contrast, no 
difference in haploinsufficiency was observed between truncating and non-truncating mutations 




Figure 6.1: NETBAG selected cluster using autism-associated de novo SNVs and CNVs. Events taken from recent 
studies, cluster P-value = 0.007. Node sizes are proportional to the importance of each gene to the final cluster 
significance, and edge widths are proportional to the likelihood each pair of genes contributes to the same 
phenotype. For clarity, only the strongest two edges from each gene are shown. Node shape indicates source of the 
gene: squares represent genes from CNV, circles from SNV, and diamonds represent genes implicated by both types 
of variation. Hierarchical clustering was applied to divide the cluster into functional groups as indicated by color 
(Figure 6.7), and general functions of these clusters were identified using DAVID as labeled (Table 6.5). Grey nodes 







Table 6.1: Clusters selected by NETBAG for various input sets 
Input set Cluster Size Cluster P-value 
Proband SNVs & CNVs 157 0.007 
Proband SNVs from O’Roak et al. 32 0.018 
Proband SNVs 62 0.019 
Proband CNVs 36 0.071 
Proband SNVs from Sanders et al. 25 0.527 
Proband SNVs from Iossifov et al. 25 0.709 
Sibling SNVs & CNVs 72 0.946 
Sibling SNVs  50 0.969 
Table 6.1: Clusters and P-values determined by NETBAG based on various input sets. Proband sets 
included 47 unique CNV loci covering 433 genes from Levy et al, 187 genes implicated through SNVs 
from O’Roak et al., 268 SNV genes from Iossifov et al., and 141 from Sanders et al. Sibling sets from 
the same sources contained 13 unique CNV loci covering 66 genes, and 352 genes implicated through 
SNVs. Sibling CNVs were not run independently due to the limited number of events.  
 
Table 6.2: Selected Gene Ontology functions associated with autism cluster 
GOID Ontology Term P-value 
GO:0045202 CC synapse 6.94e-8 
GO:0016568 BP chromatin modification 2.51e-5 
GO:0051015 MF actin filament binding 7.30e-5 
GO:0031252 CC cell leading edge 9.53e-5 
GO:0005262 MF calcium channel activity 1.47e-4 
GO:0004386 MF helicase activity 3.26e-4 
GO:0015629 CC actin cytoskeleton 4.18e-4 
GO:0030036 BP actin cytoskeleton organization 5.16e-4 
GO:0005913 CC cell-cell adherens junction 6.09e-4 
GO:0045211 CC postsynaptic membrane 6.64e-4 
GO:0016887 MF ATPase activity 8.43e-4 
GO:0044456 CC synapse part 8.66e-4 
GO:0007611 BP learning or memory 9.21e-4 
GO:0030029 BP actin filament-based process 0.001 
GO:0005938 CC cell cortex 0.001 
GO:0005911 CC cell-cell junction 0.002 
Table 6.2:  Selected Gene Ontology (GO) term annotations over-represented among genes in the 
NETBAG cluster (Figure 6.1), as identified by DAVID (david.abcc.ncifcrf.gov). P-values shown have 
been corrected for multiple hypothesis testing using Bonferroni correction available through DAVID. 
Ontology indicates GO domain; BP: Biological process, MF: Molecular function, CC: Cellular 
component. General terms associated with more than 350 human genes are not shown; for a full list 






6.2.2. Biological functions associated with autism cluster 
To explore the biological functions represented by our cluster, we used DAVID [17] to identify 
Gene Ontology (GO) terms common to our cluster genes (Table 6.2). Several interesting terms emerged 
in very different functional areas, while no GO terms were significantly enriched in either the full set of 
de novo variants or truncating SNVs. We applied hierarchical clustering to these genes based on scores 
in our underlying phenotype network and uncovered several interesting sub-clusters associated with 
distinct biological functions as labeled in Figure 6.1 (Figure 6.7). Several of these clusters contained 
genes and functions with well-documented links to autism.  
One sub-cluster contained genes responsible for synapse formation (Figure 6.1, cyan), such as 
neurexin (NRXN) and neuroligin (NRLG) as well as important scaffolding proteins localized to the 
postsynaptic density (PSD) of excitatory synapses. These functions have been known to be associated 
with ASD for several years [18-21]. A closely related sub-cluster involved primarily channel activity at the 
postsynaptic membrane (Figure 6.1, blue). This sub-cluster contained several voltage-dependent calcium 
channel genes (CACNA1B/D/E/S), and cholinergic receptors (CHRND/A7). Ca2+ signaling regulates 
neuronal excitability and has been previously implicated in ASD due to its role in synapse formation and 
dendritic growth [22]. While calcium channel activity dominated the associated GO terms, several other 
ion channel and receptor genes were also present in this cluster including: the sodium channel SCN2A 
linked to familial autism through its binding with calmodulin [23]; metabotropic glutamate receptors 
GRM5/7 relatives of genes linked to ASD through their reactions with L-glutamate, the major excitatory 
neurotransmitter in the central nervous system [24-26]; and channel receptor subunit GABRB3 which 
processes the inhibitory neurotransmitter GABA and is linked to ASD, Rett syndrome, and 
Angelman/Prader-Willi syndrome [27-29].  
 The largest sub-cluster related to functions convergent on neuronal signaling and growth, 





contained genes directly related to the growth of actin cytoskeleton (such as FLNA, CTNNA3, SPTAN1, 
NF1, and ACTN4) and to neuronal projections, axonogenesis, or dendritic formation (DCC and CYFIP1). In 
addition, there were several genes associated with cell adhesions (CTNNB1/A3 and PTPRK/M), which 
have an emerging role in ASD [30]. There were also several genes associated with neuronal signaling 
including some directly involved in axon guidance (EPHA1/B2) [31]. It also contains MAPK13/3, and 
WNK2 which modulates the activity of MAPK3, all of which affect the mTOR pathway known to regulate 
dendritic growth [32]. Overall, the large number of genes in this sub-cluster highlights the critical role of 
altered synaptogenesis, dendritic growth, and the formation and proper functioning of neuronal 
junctions in the development of ASD. 
 The final sub-cluster was functionally convergent on chromosomal modification, containing 
genes associated with helicase activity and histone modification (Figure 6.1, red). Although the 
relationships between these functions to ASD are not as well understood, there is evidence that 
chromatin regulatory mechanisms can effect neural development [33], and histone hyperacetylation 
was shown to produce autism-like behavior in mice [34]. In addition, several genes in this cluster have 
been linked to other neurodevelopmental diseases. SMARCA2, a critical hub gene in our cluster, has 
been implicated in schizophrenia through its role in chromatin remodeling [35]. MeCP2, responsible for 
Rett syndrome [36], regulates genes involved in brain function through binding to methylated DNA [37]. 
CHD7, a relative of CHD8 in our cluster, causes CHARGE syndrome, a disorder with developmental delays 
and autism-like symptoms [38]. Like the previous sub-cluster, this one also covers a broad range of 
functions potentially interesting in the study of autism. For example, the ribonuclease DICER1 functions 
with microRNAs to produce distinct neuroanatomical changes related to ASD [39, 40], and eukaryotic 
translation initiation factors (EIF2c1/3G/4A1/4G1) may be associated with ASD through altered synaptic 






6.2.3. Association of NETBAG network with functionally relevant gene sets 
 It is interesting to consider cluster genes and the wide range of functions they represent in 
relation to other gene sets relevant to related diseases and functions. Fragile X syndrome is a genetic 
disorder resulting in a spectrum of cognitive disabilities and often accompanied by autistic symptoms. It 
is caused by a failure to express the RNA-binding protein FMRP, which promotes a wide array of 
functions including synaptic plasticity and signaling. One recent study attempted to catalog FMRP 
interaction partners [43], and Iossifov et al. found a significant overlap between these genes and 
truncating mutations associated with ASD [3]. Following the method in Iossifov et al., we calculated the 
expected number of FMRP targets in our cluster using the observed overlap with a set of rare 
synonymous mutations in a healthy population [44]. We found a significantly higher overlap between 
our cluster genes and the FMRP proteins, with three times as many FMRP targets than expected by 
chance (17.6 expected, 47 observed, Binomial P-value = 1.69e-10, Table 6.3). This was comparable to the 
overlap with truncating mutations observed by Iossifov et al. While there was a modest overlap 
between FMRP targets and all genes with nonsynonymous proband SNVs (P-value = 0.034), there was 
no significant overlap with genes with nonsynonymous SNVs in unaffected siblings. We also note that 
these FMRP targets are spread across all biological functions represented in our cluster. 
 We performed a similar analysis using proteins identified in the post synaptic density (PSD) [45]. 
The PSD is a dense structure localized to excitatory synapses and crucial to signaling at synaptic 
junctions. In previous work, we demonstrated that PSD proteins have many functions in common with 
ASD-associated genes [46]. We observed a significant overlap between PSD genes and our network 
(8.5:29, Binomial P-value = 7.59e-9), and a modest overlap with truncating mutations (5.8:11, P-value = 
0.049). There was no significant overlap with either the full set of proband or sibling nonsynonymous 






Table 6.3: Overlap of various autism gene sets with FMRP targets and PSD proteins 
 
Darnell et al. FMRP Bayes et al. PSD 
Gene set Size Exp : Obs Exp : Obs % P-value Exp : Obs Exp : Obs % P-value 
Truncating SNV 107 12.0 : 25 11.2 : 23.4% 3.12e
-04
 5.8 : 11 5.4 : 10.3% 0.049 
NETBAG Cluster 157 17.6 : 49 11.2 : 29.9% 1.69e
-10
 8.5 : 29 5.4 : 18.5% 7.59e
-09
 
SNV Cluster 129 14.4 : 40 11.2 : 31.0% 1.18e
-09
 7.0 : 19 5.4 : 14.7% 7.51e
-05
 
All Proband SNV 575 64.3 : 81 11.2 : 14.1% 0.034 31.3 : 33 5.4 : 5.7% 0.713 
All Sibling SNV 354 39.6 : 49 11.2 : 13.8% 0.128 19.3 : 20 5.4 : 5.6% 0.815 
Table 6.3: We observed the rate at which FMRP targets identified by Darnell et al. or postsynaptic density proteins 
identified by Bayes et al. were hit by rare synonymous mutations in a control population from a recent analysis of 
human mutations by Fu et al. These rates (11.2% and 5.4%) allowed us to estimate the expected number of FMRP 
targets or PSD proteins in a set of mutations controlling for higher mutation rates in longer genes. We compared 
expected overlap (exp) to observed overlap (obs) and assigned significance to the observed overlaps using a two-
sided binomial test. 
 
6.2.4. Patterns of neuronal expression associated with ASD 
To investigate the dynamics of the network genes in the developing brain, we used the Human 
Brain Transcriptome database (HBT, hbatlas.org) [14], which contains gene expression data for samples 
retrieved postmortem from brains of otherwise healthy individuals of both sexes at various stages of 
development. The expression trajectories for the NETBAG cluster genes and for truncating variants 
demonstrate that genes in both sets are highly expressed in the brain, with NETBAG selected genes 
showing higher expression than truncating mutations (Figure 6.2a).   
We note that for truncating mutations there is distinctly reduced expression during the very 
earliest phases of fetal development, and we see the same pattern among CNVs. Comparing these 
mutations with the non-truncating mutations from the NETBAG cluster, we see that the two groups 
have virtually identical expression profiles (Figure 6.2b) from the mid fetal period onwards. This implies 
that while all these mutations exist in the same functional space, the relatively more severe mutations 
are not tolerated during the very earliest phases of embryonic development.  Although we did not 





neurodevelopmental processes peak in activity during the tenth post-conception week (PCW) when 
expression of genes affected by truncating mutations is highest; neuronal migration, a process 
previously implicated in ASD [47, 48], is known to begin around the seventh PCW and continue until the 
sixteenth PCW [49-51]. Thus our high expression during these periods emphasizes the importance of 
structural changes in the autistic brain. 
The high male-to-female incidence ratio is one of the distinguishing features of ASD, estimated 
at 5:1 or 7:1 for high-functioning individuals [4, 52]. It is theorized that females have unknown 
protective mechanisms, therefore requiring much stronger genetic perturbations to trigger the disorder 
[53]. This effect was observed in probands from the collection as females had fewer of the functionally 
weaker non-truncating mutations (Fisher’s exact test, one-tail P-value = 0.033), a difference 
strengthened by considering only genes in the NETBAG network (P-value = 0.019). Female probands also 
had lower IQ values overall (Female median = 72, Male median = 83, Mann-Whitney P-value = 3.37e-4). 
In addition, expression trajectories for mutations found in female probands were higher than their male 
counterparts among either truncating mutations or NETBAG implicated genes (Figure 6.2c) implying that 
their mutations hit genes which were more critical to neurodevelopment. Interestingly, among 
truncating mutations there was no significant difference in IQ values (Female median = 78, Male median 
= 79.5), however the expression profile for these genes remained much higher for females than for 
males, demonstrating that even among similar phenotypes and mutation severity female mutations 
affected genes with relatively stronger functional implications.  
Finally, we examined the expression of the functional groups defined by the hierarchical 
clustering (Figure 6.2d). Not surprisingly, postsynaptic density genes had the highest overall expression 
in the brain. Both the PSD cluster and the related channel activity cluster demonstrated a distinct rise 
during early fetal development, consistent with the occurrence of neuronal migration in early brain 





the earliest developmental phases followed by a decline approaching birth. Genes associated with actin 
growth and formation of synaptic junctions, which are involved in learning and memory formation 









Figure 6.2: Gene expression profiles in the brain across developmental stages for ASD genes. Expression data 
were obtained from the Human Brain Transcriptome database (HBT, hbatlas.org). Average expression levels were 
calculated across all genes in a given set, and error bars represent standard error of the average across samples. 
(a) Expression profiles for NETBAG cluster genes (see Figure 6.1), all disease-associated truncating mutations, and 
genes implicated through SNVs but not selected in the NETBAG network. (b) Expression for severe cluster 
mutations (all truncating SNVs and CNV genes from NETBAG cluster) and other cluster genes. (c) Expression 
profiles for cluster and truncating mutations delineated by the gender of the autistic subject. (d) Expression 





6.2.5. Temporal and regional bias in neuronal expression  
For cluster and truncating mutations, we see a notably higher expression during earlier phases 
including prenatal and late infancy periods. We calculated the expression bias as the average expression 
during these periods minus the average expression during later periods, and compared this to randomly 
generated gene sets with similar levels of overall expression in the brain. While our matched sets did 
show slightly higher expression during the early period, both cluster and truncating sets showed larger 
differences (Figure 6.3, Bias = 0.134 and 0.18, P-values = 0.03 and 0.017 respectively).  
 
Figure 6.3: Average expression difference between early developmental periods and later periods. Early 
periods defined as fetal through late infancy, later as early childhood through adulthood. Expression data 
were obtained from the Human Brain Transcriptome database (HBT, hbatlas.org) and expression 
difference was calculated as the average expression of all genes in the earlier period minus the average 
expression in the later period, so that a positive value indicates higher expression during early 
development. Random gene sets were generated by matching each disease-associated gene to a random 
gene with a similar level of overall brain expression. A distribution of expression differences across 
random sets was used to assign significance to the disease difference. Shown are distributions of random 
sets with values from the disease-associated sets as vertical dashed lines for NETBAG network genes 







The HBT database distinguishes various regions of the brain, allowing for analysis of the 
developmental trajectories across locations. The bias towards early development is present among all 
areas of the brain and significant in several regions, consistent with the pervasive nature of the 
biological functions uncovered by our analysis, and the phenotypic diversity in ASD (Figure 6.4 and Table 
6.4). The largest expression difference, however, was seen in the amygdala. This region is known to play 
a critical role in facial perception and involuntary responses to emotionally charged stimuli [54] and 
failure to recognize facial and emotional social cues are notable characteristics of ASD. Autistic 
individuals also show enhanced fear processing and response concordant with excessive amygdala 




Figure 6.4: Average expression difference across brain regions. A positive value indicating higher 
expression during periods of early development (fetal through late infancy) than later (early childhood 
through adulthood). Expression data were obtained from the Human Brain Transcriptome database (HBT, 
hbatlas.org). Error bars represent standard error of the average determined by bootstrap sampling the 
gene set. Values for truncating mutations are in blue, NETBAG cluster genes in orange, and sibling SNVs in 
green. Random gene sets were generated by matching each disease-associated gene to a random gene 
with a similar level of overall brain expression and the distribution of random differences was used to 






6.2.6. Phenotypic variation in ASD-associated genes 
 Along with genetic variants, the SSC collected numerous test results measuring the severity of 
the disease including: the Autism Diagnostic Interview-Revised (ADIR, both sections on social interaction 
and restricted and repetitive behaviors), Social Responsiveness Scores (SRS), and the Autism Behavior 
Checklist (ABC). They also measured general IQ, as well as verbal and non-verbal IQ values. We found 
that some measurements had an impact on gene expression levels, while others affected a gene’s 
Table 6.4: Early development expression bias calculations for regions of the brain 












amygdala 0.217 0.218 0.069 0.005 0.095 2.231 0.013 
cerebellum 0.198 0.197 0.071 -0.002 0.096 2.077 0.021 
frontal 0.109 0.109 0.069 0.014 0.097 0.973 0.164 
hippocampus 0.136 0.135 0.067 0.021 0.092 1.244 0.108 
occipital 0.148 0.149 0.075 0.014 0.101 1.325 0.092 
parietal 0.110 0.111 0.067 0.013 0.096 1.003 0.157 
temporal 0.135 0.136 0.067 0.007 0.095 1.339 0.088 
thalamus 0.130 0.130 0.072 0.039 0.092 0.989 0.158 





Bootstrap estimation Expression-matched genesets 
Average bias Bias standard 
error Average bias 
Bias standard 
deviation Z-score P-value 
amygdala 0.261 0.260 0.083 0.002 0.114 2.263 0.012 
cerebellum 0.154 0.154 0.090 -0.002 0.117 1.339 0.089 
frontal 0.170 0.171 0.082 0.012 0.118 1.339 0.088 
hippocampus 0.180 0.179 0.083 0.019 0.112 1.450 0.072 
occipital 0.164 0.165 0.087 0.011 0.124 1.233 0.105 
parietal 0.155 0.154 0.083 0.011 0.117 1.222 0.109 
temporal 0.185 0.185 0.079 0.005 0.115 1.561 0.060 
thalamus 0.223 0.222 0.080 0.037 0.111 1.679 0.045 
ventral 0.225 0.223 0.094 0.008 0.131 1.647 0.047 
Table 6.4:  We examined the bias of ASD towards earlier stages of life by comparing expression during early 
developmental periods (fetal through late infancy) with later periods (early childhood through adulthood) 
across various regions of the brain.  Expression data were obtained from the Human Brain Transcriptome 
database (HBT, hbatlas.org). The difference between the average expression levels during both periods was 
calculated, where a positive value indicates a greater bias towards early development. Bootstrap sampling of 
each gene set was used to calculate the error around the early bias value. Significance was determined by 
comparison with the bias uncovered in random gene sets where genes were selected with matching 





contribution to the significance of the NETBAG cluster. Interestingly general IQ affected both, indicative 
of the broad factors measured by intelligence tests.  
First, to explore the effect of phenotypic variation on gene expression, we divided genes into 
subsets based on phenotype measurements. We divided genes at the median value of a particular 
measurement and plotted expression of higher and lower scoring subsets. Mutations from subjects with 
lower IQ scores, or higher ADIR (both indicating more severe damage) were associated with higher 
overall expression in the brain (Figure 6.5). This was true for all truncating genes and all genes from the 
NETBAG cluster. We note that the pattern is less distinct for cluster genes, possibly reflecting the 
method’s purpose of finding functionally related genes.  
 
 
Figure 6.5: Expression by phenotype measurements. Subjects were divided into two groups based on 
their phenotype scores and divided at the median score for the entire set. Scores associated with more 
severe damage are shown in red, less damage in blue. Cluster genes are plotted using solid lines, 
truncating genes using dashed lines. (A) Subject divided by their full scale, or combined verbal and non-
verbal IQ scores, median of 78. (B) Subjects divided by their scores on Autism Diagnostic Interview 
Revised, social interaction section, median of 21. (C) Subjects divided by their scores on the ADIR, 
restricted and repetitive behaviors section, median of 6. 
 
As it had the most consistent impact on our results, we chose to examine IQ in greater detail. 





IQ scores; truncating mutations were associated with lower IQ scores (truncating median IQ = 79, non-
truncating median IQ = 83, Mann-Whitney, one-tail P-value = 0.09). In addition, NETBAG selects genes 
from subjects with lower IQ scores regardless of mutation severity. We considered three sub-
populations: those who were likely unaffected by their mutation and had an average or higher IQ (above 
100), those who were potentially affected having an IQ on lower side but within one standard deviation 
of average (between 80-100), and finally those subjects with more compromised IQs (below 80). While 
23% of all SNVs are selected in our cluster, subjects with the lowest IQ values contribute more genes 
(26%) while subjects with moderate IQ values contribute fewer (20.4%). Subjects with the highest IQ 
values are significantly under-represented in our cluster (18.1% selected in cluster, Fisher’s exact test P-
value = 5.0e-4). This suggests that functions uncovered by the NETBAG+ algorithm may be particularly 
relevant to reduced IQ.  
Focusing on only cluster genes, we examined the effect of phenotype on a particular gene’s 
contribution to the overall network significance. Each gene contributes to the score and significance of 
the final network based on its connections to all other genes in the network; therefore genes with a 
great degree of functional relevance to the disease will have higher contribution scores. Comparable to 
our expression results, we found that genes which contributed less to the cluster score were associated 
with higher IQ values (Figure 6.6a, Mann-Whitney, one-tail P-value = 0.021). Finally, we also examined 
the association of IQ to the different functional sub-clusters identified (Figure 6.6b). We found that 
mutations genes associated with neuronal structure and signaling (Figure 6.1, green) were associated 
with lower IQ scores than other cluster genes (median IQ in sub-cluster = 67, in remaining cluster = 83, 
Mann-Whitney P-value=0.005). In contrast, genes associated with chromosomal modification (Figure 
6.1, red) were associated with higher IQ scores than the rest of the cluster (median IQ in sub-cluster = 







Figure 6.6: Histograms showing distribution of subject IQ based on gene subsets. Shown is full scale IQ 
which combines including verbal and non-verbal IQ. (A) Cluster genes are divided based on their 
contribution to the final cluster score and significance. Genes with higher contribution (red) were more 
important to cluster significance and associated with stronger effects or more reduced IQ values. Median 
IQ values for high contribution genes was 73, for low contribution genes was 81. (B) Distribution for 
functional sub-clusters from Figure 6.1. Median values were 67 for neuron structure and signaling (green), 




Our analysis clearly demonstrates that the phenotypic heterogeneity of autism spectrum 
disorders is mirrored by diversity in mutation type, biological function, and gene expression patterns. 
Genes affected by de novo mutations converged on multiple biological pathways, each with distinct 
expression profiles. Despite this variety, several interesting results emerged across biological functions 
and mutation types.   
We observed a significant bias towards higher gene expression during prenatal and early infancy 
periods, with maximum expression typically occurring during the mid-fetal periods. The emphasis on 
these early periods is consistent with the typical onset of ASD in early childhood and our understanding 
of it as a disease of neurological development. Despite the variation in gene expression across functions, 





mutations. Elevated gene expression in the brain was consistent with more substantial phenotypic 
alterations, as witnessed by the impact of expression on IQ and other phenotype measurements. In 
addition, it has often been suggested that females have unknown protective mechanisms against ASD, 
and thus require stronger genetic perturbations in order to trigger the phenotype.  This is further 
supported by higher average expression for genes with identified mutations from female subjects. There 
has been recent focus on truncating mutations in ASD. We see the importance of such mutations in 
determining phenotype through their relatively stronger impact on IQ and other phenotype 
measurements. However, our method, which is agnostic to mutation severity, suggests that non-
truncating mutations also significantly contribute to the disease.  
Taken together, our work validates the importance of combining data from multiple sources and 
using a method such as NETBAG to find the biological processes underlying a complex disease like ASD. 
In addition, we show that the key properties of mutations – such as their severity, function, and 
expression – can directly influence the phenotype of the individual, an important step towards using 






ASD associated de novo variants.  
Variants were obtained from four recent studies of families in the Simons Simplex Collection and 
included de novo copy number variants (CNVs) [4] and de novo single nucleotide variants (SNVs) [3, 5, 
6]. Overlapping CNVs were combined into a single event. When SNV genes were contained within CNV 
events, the SNV gene was considered individually while the remaining genes in the CNV were considered 
as a separate event. After combining overlaps and removing duplicate genes the set contained 985 
genes at 619 distinct genomic locations remained; 433 genes at 47 distinct loci from Levy et al., and 573 
SNVs, 141 from Sanders et al., 187 from O’Roak et al., and 269 from Iossifov et al. 
 
Phenotype network and the NETBAG algorithm 
 NETBAG relies on our previously defined phenotype network in which all pairs of genes are 
assigned a score proportional to the likelihood that those genes are involved in a shared phenotype [46, 
56]. Genes implicated by ASD-associated variants were mapped to this phenotype network and a greedy 
search algorithm was used to find the highest scoring cluster at each size. Cluster score is the sum of 
contributions from each gene, and each gene contributes based on a de-weighted sum of the edges 
between it and other cluster genes. De-weighting, in which the sum is the strongest edge plus half of the 
second strongest edge, plus one third of the third strongest edge and so on, reflects our belief that 
because all cluster genes share common functions their edges are not wholly independent. The 
significance of the best cluster at each size is determined through comparison with clusters built from 
randomly generated events. The cluster size with the strongest significance is selected and the P-value is 
adjusted for multiple hypothesis correction as we have examined clusters of multiple sizes. 
Random events were constructed by sampling genes that match both protein length and overall 





significance is not driven by disease genes with high overall connectivity in the phenotype network, or 
by genes more susceptible to mutations due to longer sequence length. Similar results were obtained by 
comparison with random events generated by selecting genes based on synonymous mutation rates 
taken from a large study of rare mutations in healthy population [44]. This also ensures that significance 
is not affected by the length of particular genes in the input set, as longer genes will also be more likely 
to be selected for random trials, but it does not rely on any information in the underlying phenotype 
network. 
A distribution of cluster scores from random trials was used to assign significance to disease-
associated clusters at each size. Then for each random trial the most significant P-value is selected 
regardless of size and a distribution of best P-values is used to assign a final significance to the disease-
associated cluster. The final P-value represents the strength of the connections in a cluster and the 
probability of finding a similarly interconnected cluster of any size among random trials, thus correcting 
for multiple hypothesis testing due to consideration of networks of different sizes. Clusters with five 
genes or fewer were ignored to ensure that trivial gene networks did not influence our analysis. 
In this analysis we found that many clusters shared the same, highly significant P-values. We 
therefore defined a z-score for each cluster based on scores from clusters of the same size found using 
random events and selected the final cluster based on a combination of P-value and z-score.  
 
FMRP and PSD enrichment of ASD gene sets  
We calculated the expected number of FMRP targets or PSD-associated proteins for a particular 
gene set by using the observed overlap between FMRP or PSD genes within a set of rare synonymous 
mutations from a recent large-scale survey of human genetic variation [44]. This ensures that 





two-sided binomial test to assign P-values to the observed overlaps between disease gene sets and 
FMRP targets or PSD-associated proteins. 
 
Hierarchical clustering  
An implementation of hierarchical clustering available in R was used to separate the NETBAG 
results into functional sub-clusters. Pairwise distances between genes were computed by taking the 
inverse of the corresponding likelihood score from the phenotype network, such that gene pairs with 
stronger phenotype scores were considered closer together. Clusters were joined using average linkage.  
 
Brain expression trajectories 
High throughput gene expression data were obtained from the Human Brain Transcriptome [14] 
(HBT, hbatlas.org) database. This database contained gene expression from multiple post-mortem 
samples of healthy human brains. Preprocessing of expression microarray measurements included 
quantile normalization and log2 transformation across all samples. To investigate trajectory of gene 
expression in the brain, we calculated the average for all genes in a given subset at each of the 15 
developmental stages, (from embryonic to late adulthood).  
 
Brain expression difference between early and late development  
To characterize the relationship between brain expression during phases of early development 
(fetal through late infancy, 4 post-conception weeks to 1 year of age) and later phases (early childhood 
through adulthood, 1 year to 60 years of age), average expression for each age range was computed and 
the difference determined for each region of the brain. A positive value indicates higher expression 
during periods of early development. The standard error of the average was calculated by bootstrap 





matching each disease-associated gene to a random gene with a similar level of overall brain expression. 
The brain expression difference was calculated for each random gene set and a distribution of 
differences for 10,000 such random trials was used to assign a P-value to the observed brain expression 
difference for a given disease gene set.  
 
Figure 6.7: Hierarchical clustering of genes selected by NETBAG. Pairwise distances between genes were 
determined using the phenotype network such that genes with strong functional links were considered 
closer together. Clustering was performed using R with average linkage to join clusters. Clusters were 
assigned the following functions using DAVID: green represents neuronal signaling along with actin 
growth and neuronal projection, red represents chromosomal modification, blue represents calcium 
channel activity and signaling at the postsynaptic membrane, cyan represents genes localized to the post 







Figure 6.8: Gene expression profiles for disease-matched gene sets. Expression data were obtained from the 
Human Brain Transcriptome database (HBT, hbatlas.org). Average expression levels were calculated across all 
genes in a given set, and error bars represent standard error of the average across samples. Shown are expression 
trajectories for NETBAG cluster genes (see Figure 6.1) along with random genes selected to match cluster genes 
based on various criteria. Genes were matched using protein sequence length (blue), average connectivity in the 






Table 6.5: Gene Ontology terms significantly associated with functional clusters 
Postsynaptic density (Figure 6.1, cyan) 
GOID Ontology Term P-value 
GO:0044456 CC synapse part 1.77 e
-07
 
GO:0014069 CC postsynaptic density 5.17 e
-06
 
GO:0045211 CC postsynaptic membrane 6.91 e
-05
 
GO:0004385 MF guanylate kinase activity 0.001 
GO:0007268 BP synaptic transmission 0.005 
GO:0019201 MF nucleotide kinase activity 0.006 
GO:0016776 MF phosphotransferase activity, phosphate group as acceptor 0.012 
GO:0019205 MF nucleobase, nucleoside, nucleotide kinase activity 0.021 
GO:0048489 BP synaptic vesicle transport 0.037 
Channel activity (Figure 6.1, blue) 
GOID Ontology Term P-value 
GO:0005261 MF cation channel activity 1.64 e
-14
 
GO:0005262 MF calcium channel activity 6.77 e
-12
 
GO:0006816 BP calcium ion transport 5.26 e
-11
 
GO:0015674 BP di-, tri-valent inorganic cation transport 3.73 e
-10
 
GO:0034702 CC ion channel complex 1.02 e
-08
 
GO:0005245 MF voltage-gated calcium channel activity 3.34 e
-08
 
GO:0022843 MF voltage-gated cation channel activity 7.26 e
-08
 
GO:0022832 MF voltage-gated channel activity 5.25 e
-07
 
GO:0005244 MF voltage-gated ion channel activity 5.25 e
-07
 
GO:0034703 CC cation channel complex 7.16 e
-05
 
GO:0022834 MF ligand-gated channel activity 7.95 e
-05
 
GO:0015276 MF ligand-gated ion channel activity 7.95 e
-05
 
GO:0005891 CC voltage-gated calcium channel complex 3.61 e
-04
 
GO:0034704 CC calcium channel complex 6.82 e
-04
 
GO:0044456 CC synapse part 0.002 
GO:0045211 CC postsynaptic membrane 0.003 
GO:0019932 BP second-messenger-mediated signaling 0.007 
GO:0007187 BP G-protein signaling, coupled to cyclic nucleotide second messenger 0.008 
GO:0042383 CC sarcolemma 0.011 
GO:0019935 BP cyclic-nucleotide-mediated signaling 0.012 
GO:0005230 MF extracellular ligand-gated ion channel activity 0.016 
GO:0007268 BP synaptic transmission 0.020 
GO:0030315 CC T-tubule 0.039 
DNA Modification (Figure 6.1, red) 
GOID Ontology Term P-value 
GO:0016568 BP chromatin modification 7.48 e
-13
 
GO:0004386 MF helicase activity 1.92 e
-10
 
GO:0042623 MF ATPase activity, coupled 5.23 e
-05
 
GO:0016569 BP covalent chromatin modification 2.39 e
-04
 
GO:0016585 CC chromatin remodeling complex 4.27 e
-04
 
GO:0000123 CC histone acetyltransferase complex 0.003 
GO:0016570 BP histone modification 0.004 
GO:0070035 MF purine NTP-dependent helicase activity 0.004 
GO:0008026 MF ATP-dependent helicase activity 0.004 
GO:0016573 BP histone acetylation 0.019 





Table 6.5: Gene Ontology (GO) term annotations identified by DAVID among genes in each of the sub-clusters from 
the NETBAG results (Figure 6.1). P-values have been corrected for multiple hypothesis testing using Bonferroni 
correction available through DAVID. Ontology indicates GO domain; BP: Biological process, MF: Molecular function, 
CC: Cellular component. General terms associated with more than 350 human genes are not shown. 
(cont.) DNA Modification (Figure 6.1, red) 
GOID GOID GOID GOID 
GO:0000122 BP negative regulation of transcription from RNA polymerase II promoter 0.033 
GO:0017053 CC transcriptional repressor complex 0.041 
GO:0000118 CC histone deacetylase complex 0.041 
GO:0000122 BP negative regulation of transcription from RNA polymerase II promoter 0.033 
GO:0017053 CC transcriptional repressor complex 0.041 
GO:0000118 CC histone deacetylase complex 0.041 
GO:0043543 BP protein amino acid acylation 0.046 
Neuron structure and signaling (Figure 6.1, green) 
GOID Ontology Term P-value 
GO:0051015 MF actin filament binding 9.80 e
-9
 
GO:0015629 CC actin cytoskeleton 5.93 e
-8
 
GO:0030036 BP actin cytoskeleton organization 3.79 e
-7
 
GO:0031252 CC cell leading edge 4.67 e
-7
 
GO:0005913 CC cell-cell adherens junction 7.51 e
-7
 
GO:0030029 BP actin filament-based process 7.94 e
-7
 
GO:0004713 MF protein tyrosine kinase activity 5.93 e
-6
 
GO:0005911 CC cell-cell junction 7.71 e
-6
 
GO:0031175 BP neuron projection development 2.08 e
-5
 
GO:0005912 CC adherens junction 2.48 e
-5
 
GO:0070161 CC anchoring junction 5.52 e
-5
 
GO:0004714 MF transmembrane receptor protein tyrosine kinase activity 7.52 e
-5
 
GO:0001725 CC stress fiber 4.30 e
-4
 
GO:0007507 BP heart development 5.96 e
-4
 
GO:0032432 CC actin filament bundle 6.02 e
-4
 
GO:0022603 BP regulation of anatomical structure morphogenesis 6.96 e
-4
 
GO:0042641 CC actomyosin 7.05 e
-4
 
GO:0007169 BP transmembrane receptor protein tyrosine kinase signaling pathway 8.41 e
-4
 
GO:0005916 CC fascia adherens 0.001 
GO:0030027 CC lamellipodium 0.001 
GO:0000904 BP cell morphogenesis involved in differentiation 0.002 
GO:0022604 BP regulation of cell morphogenesis 0.002 
GO:0005938 CC cell cortex 0.004 
GO:0014704 CC intercalated disc 0.005 
GO:0005516 MF calmodulin binding 0.006 
GO:0048812 BP neuron projection morphogenesis 0.006 
GO:0030425 CC dendrite 0.008 
GO:0045296 MF cadherin binding 0.010 
GO:0043531 MF ADP binding 0.014 
GO:0044449 CC contractile fiber part 0.015 
GO:0048858 BP cell projection morphogenesis 0.017 
GO:0043292 CC contractile fiber 0.021 
GO:0032990 BP cell part morphogenesis 0.023 
GO:0007409 BP axonogenesis 0.031 
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